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1. Histamine and Histamine receptors 
 At the beginning of the  20th century, histamine (Figure 1.) was synthesized as 
chemical curiosity by Windaus and Vogt before its presence in the tissues was 
 recognized.' In 1910, its physiological responses such as vasodilatation, smooth 
muscle contraction and gastric acid secretion were described by Dale and his 
colleagues,2 and they isolated histamine as picrate crystalline from the lung and liver 
of cattle in  1927.3 Histamine is closely associated with mast cells in mammalian 
tissues, but it has also been detected in platelets, enterochromaffin-like c lls, and 
endothelial cells.4 
 Beside the peripheral tissues, histamine is widely distributed within the central 
nervous system (CNS) as a neurotransmitter or neuromodulator. In the CNS, 
histamine is synthesized in a restricted population of neurons located in the 
tuberomammillary nucleus of the posterior  hypothalamus5 and is implicated in several 
functions uch as stimulation of hormone release, regulation of sleep/wake cycles, and 
modulation of cognition.6'7 
 In 1937, Bovet and Staub discovered the first compounds, piperoxan and 
thymoxyethyldiethylamine, that competitively antagonized the effect of histamine 
response on allergic  reactions.8 The intensive research resulted in the development of 
several potent "anti-histamines", which were introduced for clinical use. It was soon 
recognized that these compounds did not block all actions of histamine. For example, 
histamine stimulated gastric secretion was shown to be unresponsive by the 
 "anti-histamines".9 In 1966, Ash and Schild proposed the nomenclature H1- for 
receptors blocked by the "anti-histamines". They described hypothesis that the actions 
of histamine not blocked by "anti-histamines" were mediated through a second type of 
receptor. This theory has accepted when Black and his co-workers synthesized and 
reported burimamide, which inhibit the effect of histamine on the gastric acid 
 secretion.1° 
 About 15 years after the discovery of the H2- receptor, the existence of a third 
histamine receptor subtype, controlling the release and synthesis of histamine was 
suggested by Arrang and  colleagues." The existence of the histamine H3- receptor 
was validated by the development of the highly selective and potent H3- agonist 
 (R)-a-methylhistamine and the H3- antagonist hioperamide in 1987.12 
 At the turn of the  20th century, the progress of molecular biological technique has 
lead the identification of a new histamine receptor, the H4- receptor.13 The unique 
expression profile of the  H4- receptor suggests that it may be a new target in the 
regulation of immune function. However, the function of the H4- receptor has not yet 
been established. 
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Figure 1. Chemical structure of histamine
2. Molecular biology of histamine receptors 
 Recent developments in molecular biology have enabled clarification of the 
molecular structures of histamine receptors, and the subclassification of histamine 
receptors based on traditional pharmacological methods was confirmed. In 1991, the 
gene encoding for the histamine H1- and H2- receptors have been cloned.14,15 The 
cloned genes encode a 56-kDa protein with 487 amino acids for a human  H1 receptor 
and 40-kDa protein with 359 amino acids for a human H2- receptor. The identification 
of the histamine H3- receptor came nearly a decade later by Lovenberg. The gene 
encoding of the histamine H3- receptor  is  49-kDa with 445 amino acids for a human.16 
Although the H4- receptor shows little overall sequence homology to H1- and  H2-
receptors, it was found to be discovered in the quest for new seven transmembrane 
GPCR sharing homology to the H3- receptor.13 
 The amino acids sequence comparison among the human, mouse, rat, and guinea 
pig H1- receptors indicated an overall 72 to 78 % homology. The other histamine H2-, 
H3-, and H4- receptors indicated overall 85 to 86 %, 92 to 93 %, and 64 to 69 %, 
respectively. (Figure 2.) The degree of homology between the H4- receptors from 
different four species is the lowest among the histamine receptor family, whereas 
homology comparison of H3- receptors revealed > 92 % overall sequence identity 
across the species. (Figure 2.) The amino acids sequence of H4- receptor is very 
similar to that of H3- receptor. The percentage of homology between the H3- and  H4-
receptors of each species is 34 to 50 %. (Figure 3.) 
 The histamine H1- receptor is a  Ca2+ mobilizing receptor, which is associated with 
the phospholipase C (PLC) catalyzed hydrolysis of membrane inositide  phospholipids 
and couples to the members of the  Go1 family of G proteins.17 The H2- receptor is 
coupled to the adenylate cyclase system, and activates adenylate cyclase.17 On the 
contrary, an inhibition of cAMP accumulation in response to histamine was observed in 
forskolin stimulated cells expressing the histamine H3- and/or H4- receptors mediated 
by pertussis toxin sensitive G110 G-protein.13
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Figure 2. Homology comparison by amino acid of the human (H), guinea pig (G), mouse (M), and rat (R) 
H1-, H2-, H3-, and H4- receptors. Percentage of overall homology was determined using the entire amino 
acid sequence according to DNASIS program.
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Figure 3. Amino acid alignments of H1, H2, H3, and H4 receptors in the human (h), guinea pig (g), mouse 
(m), and rat (r). Percentage of overall homology was determined using the entire amino acid sequence 
according to DNASIS program.
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3. Distributions of H3- and H4- receptors 
 The histamine H3- receptor is expressed in the smooth muscle, endothelial cells, 
adrenal medulla, heart, and central nervous system (CNS) as a presynaptic 
autoreceptor, which modulates transmitter release via a negative feedback 
mechanism in a variety of neurons, including the histaminergic, adrenergic, cholinergic 
and serotonergic  neurons.18-27 On the other hand, the histamine H4- receptor was 
expressed in the bone marrow, spleen, peripheral blood mononuclear cells, 
neutrophils, eosinophils, and mast  cells.13'28-34 The distribution of H4- receptor 
suggests that histamine may play a new role in immune and/or inflammatory 
modulation through the new  receptor.35'36 
4. H3- Agonists and H3- Antagonists 
 The first potent and selective ligands for the H3- receptor are (R)-a-methylhistamine 
as an agonist (Figure 4.) and thioperamide as an antagonist (Figure 5.), which have 
been used as standard ligands in pharmacological in vitro and in vivo  studies.37'38 The 
immepip and imetit, in which the amino group of histamine was substituted by the 
piperidine ring and isothiourea moiety, respectively, exhibited high H3- receptor 
agonistic potency. (Figure  4.)39'40'41 (R)-a-methylhistamine shows the histamine  H1-
receptor and a2-adrenoceptor agonistic activity, whereas imetit is shown to act as a 
moderate 5HT3- receptor agonist. Moreover, immepip acts as an  l-14- receptor agonist 
as well. 
 The side chain of compounds with H3- antagonistic activity display an even larger 
heterogeneity than the side chain of H3- agonists. The potent H3- antagonists have 
been found substitution with carbamate, ester, ether, and amide group. For example, 
the incorporation of an isothiourea moiety in the side-chain gives the highly potent  H3-
receptor antagonists, clobenpropit and iodophenpropit (Figure 5.). These compounds 
were developed as N-substituted erivatives of  imetit. Their potencies as H3- receptor 
antagonist are about 10 times more potent han  thioperamide.18'42 
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Figure 4. Structure of (R)-a-methylhistamine, Immepip, and  Imetit
Thioperamide
lodophenpropit
Clobenpropit
          Figure 5. Structure ofThioperamide, lodophenpropit, and Clobenpropit 
5.  H4- Agonists and H4- Antagonists 
 As the human histamine H4- receptor revealed the highest overall similarity with the 
H3- receptor, most of potent, classical H3- agonists also have H4- agonistic activity, but 
with a reduced potency. On the other hand, the potent and non-imidazole  H3-
antagonists uch as  4-(3-piperidin-1-yl-propoxy)benzonitrile lack the activity at the  H4- 
receptor.31 In contrast, an atypical antipsychotic drug, clozapine, shows moderate 
activity on the H4- receptor and no activity on the H3-  receptor.43 Novel compounds, 
OUP-13 and OUP-16, that have been discovered by our group, exhibited selective 
agonistic activity for H4- receptor as described in this thesis. Recently, Jablonowski 
and co-workers have described a series of potent and selective non-imidazole 
histamine H4- receptor antagonists. The indolylpiperazine derivatives, which are 
substituted on 5 or 7 positions of the indole ring, showed high affinity for the histamine 
H4- receptor and were found to be >1000-fold selective for the H4- receptor over the 
other histamine  receptors.44 
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6. Aim of this thesis 
 When I started this study in 1999, cloning of histamine H3- receptor cDNA had not 
been completed yet. In the same year, our group  discovered imifuramine, 
 4(5)-[5-(Aminomethyl)-tetrahydrofuran-2-yl]imidazoles as a potent H3- receptor agonist 
using in vivo microdialysis of  rats.45•46 Imifuramine is a member of 
tetrahydrofuranylimidazole d rivatives synthesized by Dr. S. Harusawa in Osaka 
University of Pharmaceutical Sciences. The aim of this study is to design potent and 
selective histamine H3- and/or H4- receptors ligands using in vivo and in vitro assays 
systems. 
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Abstract 
 (+)-4(5)-[(2R,5R)-5-Aminomethyltetrahydrofuran-2-Aimidazole [(+)-1,imifuramine] and 
its  2R,5S-stereoisomer (+)-2 were expected as base compounds to develop selective 
human histamine H4- receptor ligands. The improved synthesis of (+)-1 was done via 
cyclization of a diazafulvene intermediate generated by Bu3  P/N,N,NWV-tetramethyl 
azodicarboxamide (TMAD) treatment of a diol  17ab bearing an unsubstituted imidazole 
moiety in good yields. This methodology also afforded an alternative synthetic route to 
trans- and cis-ethyl  4(5)-(5-hydroxymethyltetrahydrofuran-2-yl)imidazole  c rboxylates 
(5 and 6), reported previously. Also,  4(5)-[(2R,5S)-5-aminomethyltetrahydrofuran-2-yl] 
imidazole  (+)-2 was synthesized from ethyl  4(5)-(2-deoxy-J3-D-ribo-furanosyl) 
 imidazole-1-carboxylate (35) via the four steps involving deoxygenation. 
• 
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 Histamine H4  (H4- receptor is the most recently discovered histamine receptor 
which has approximately 35% overall homology to the human histamine H3 (H3-) 
 receptor.") However, the tissue distribution of the two receptors is quite different. The 
H3- receptor is mainly found in the central nervous system, whereas the mRNA of the 
H4-receptor is expressed exclusively in peripheral tissues, such as bone  marrow,1 
small  intestine,l'"  spleen,w) and  leukocytes! The physiological and 
pathophysiological functions of the receptor are unknown. However, the abundant 
expression of human H4- receptor mRNA in the  hematopoietic and lymphatic tissues 
indicates that the receptor might be related to regulation of hematopoiesis and/or an 
immune function. To investigate the pharmacology of the receptor, specific ligands are 
indispensable, but most H3- ligands are active at the H4- receptor as well and no 
specific ligands for the H4- receptor are  available.8) 
 We very recently examined the binding affinity and functional activity of 
2,5-disubstituted tetrahydrofuranylimidazoles for human H3- and H4- receptors 
expressed in SK-N-MC  cells.9) Among them,  (+)-4(5)-[(2R,5R)-5-aminomethyl-
tetrahydrofuran-2-yl] imidazole  [(+)-1,  imifuramine]10'11) exhibited potent agonistic 
activities for the H3- receptor, while its enantiomer  (-)-1 was found to be a selective  H3- 
agonist, which was approximately 300-fold more active at the H3- receptor 
than the H4- receptor (Fig. 1). It is of particular interest to find that methyl 
cyanoguanidine derivatives (-)-3 (OUP-16) and  (+)-4  (OUP-13) exhibited full  agonistic 
activities for the H4- receptor with 40- to 45-fold selectivity over the H3- receptor. 
Hence, the two OUP compounds would be lead compounds to develop selective 
human H4- receptor  ligands.8) 
 We previously reported a stereodivergent synthesis of trans- or  cis-4(5)-(5- 
aminomethyltetrahydrofuran-2-yl- or 5-aminomethy1-2,5-dihydrofuranyl)imidazoles, 
which is characterized by use of a- or  j3-phenylselenenyl nucleosides 7 or 8 as key 
intermediates (Fig.  1).10-12) Although the synthetic strategy was effective as an initial 
step for accessing these compounds, it lacks the stereoselective formation of 7 or 8 
 and, further, requires phenylselenenylation anddeselenenylation steps in the synthetic 
sequence. On the other hand, we reported an efficient and stereoselective synthesis 
of /3-imidazole C-nucleosides bearing 4(5)-substituted imidazole as a common 
structural unit, using the cyclization of  1,3-diazafulvene generated in situ (Chart  1).13,14) 
In that report, we also indicated that an unsubstituted imidazole moiety is 
indispensable for the generation of the diazafulvene 10, and the  benzyloxy group at 
the C2'-position of the substrate 9RS (di-astereomeric mixtue at  C1') acts as the 
directing group to control the stereochemistryof/3-imidazole C-nucleoside 11/3.13,14) 
The methodology was recently extended to stereocontrolled synthesis of heterocyclic 
C-nucleosides (indole, C-2 linked imidazole, benzimidazole, and 6-iodobenzimidazole) 
by Benhida et  al.15'166 In such circumstances, the findings of OUP-16 and 13 
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encouraged us to synthesize trans-
or cis-tetrahydrofuranylimidazoles 
using the diazafulvene-cyclization. 
 We herein describe a simple and 
effective synthesis of imifuramine 
 [(+)-1] via a diazafulvene 
intermediate. Also, this synthetic 
method was independently used for 
the synthesis of trans- and cis-ethyl 
 4-(5-hydroxymethyltetrahydrofurany 
 I)-imidazole-  1-carboxylates 5 and 6, 
useful intermediates in our quest for 
specific H4-ligands. Further,  4(5)- 
[(2R,5S)-5-aminomethyltetrahydrofu 
 ran-2-yl]imidazole [(+)-2], which is a 
substrate of OUP-13, was efficiently 
synthesized from ethyl 
 4(5)-(2-deoxy-p-D-ribofuranosyl) 
 imidazole-1-carboxylate (35).
Fig. 1
Synthesis of Imifuramine We 
recently reported that intramolecular 
Mitsunobu reaction of a diol  14ab  17) 
 (1  : 1 diastereomeric mixture), which 
was prepared starting from 
(R)-benzyloxymethyl-y-butyrolacton 
e  (12)  ,18) with  N,N,Nn,N"-tetramethyl 
azodicarboxamide  (TMAD)19) and 
Bu3P followed by desilylation affords 
trans- and cis-cyclization products 
15 (47%, 9% ee) and 16 (53%, 20% 
ee) with low optical puritie (Chart 2). 
The low optical purities were 
attributed to indistinguishable
activities between two hydroxy groups of  14ab." Thus, we directed our attention to 
imifuramine synthesis using diazafulvene cyclization. Hydrolysis of  14ab in refluxing 
1.5 N HCI afforded a diol  17ab having unsubstituted  imidazole in 95% yield. The 
cyclization of  17ab was examined under various conditions to optimize the yield of the 
trans-product.  14,20) The results are summarized in Table 1. When the reaction of  17ab 
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was first carried out using TMAD and Bu3P at  rt in tetrahydrofuran (THF) for 2 h, a 
crude tetrahydrofuranylimidazole  18ab was obtained. The crude mixture was then 
treated with ethyl  chloroformate to separate it from the  Bu3P5O by-product, followed 
by column chromatography to afford a 2.3 : 1 mixture of trans- and 
cis-N-ethoxycarbonylated products 23a and 23b in only 12% overall yield from  17ab 
(Table 1, run 1). In the case of  THF (Table 1, run 1-3), the reaction was suppressed to 
give low yields, but the yields of 23ab were improved to 56% or 50% yields in benzene 
or toluene, respectively (run 4 and 5). Further, the use of CH2Cl2 at 0 °C increased the 
yield to 80% with a 3 : 1 ratio of trans- and  cis-products (run 7). The predominant 
formation of the trans-isomer was also observed in CH2Cl2 at 235 °C, but in only 15% 
yield (run 8). From these results, it became clear that the reaction was significantly 
influenced by the selection of solvents. 
 The structures of 23a and 23b were assigned on the basis  of  11-I-NMR. The C5'-H  (8 
4.32-4.55, m,  51-I and  CO2CH2  )
Chart 1
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Reagents and conditions : a) (i) DIBAL, -70°C; (ii) 13, THF, -70 to -50°C then  rt; 
b) aq. 1.5 N  Ha -  THF  (1  :1), reflux, 4h;  c) Bu3P (1.5 eq), TMAD (1.5 eq),  CH2Cl2, 
0°C, 15h; d)  Boc2O; e) H2, 10% Pd-C; f) (i) Phthalimide, Ph3P, DEAD; (ii)  SIO2 
separation; g) hydrazine hydrate
Chart 2
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Table 1. Solvent Effects of Cyclization to 23ab
i) TMAD (1.5 eq) 
 Bu3P  (1.5eq) 
 2h
 EtO2C\
N-,.,..17 
\----N
 0 OBn
 17ab  ii^
ii) CICO2Et
23a (trans) 
23b (cis)
Run Solvent Temp. (°C) Yield (%) 23a/23b
1  THF Rt 12 2.3/1
2  THF 0 12 3/1
3  THF Reflux 15 2/1
4 Benzene  Rt 56 2/1
5 Toluene 0 50 2/1
6 CH2Cl2 rt 68  1/1
7 CH2Cl2 0 80 3/1
8 CH2Cl2 -35 15 5/1
in trans-23a was observed in lower field in comparison with that  (S 4.16-4.31, m) in 
 cis-23b, because of the deshielding effect of the imidazole ring located syn in  23a.17) 
 At a practical evel, a serious drawback of the N-ethoxy-carbonyl product 23ab is the 
difficulty in separating the respective  trans- and cis-isomers 23a and 23b by SiO 2 
column chromatography. It required a large column to avoid contamination of the 
trans-product by the  cis-isomer. After many trials, we found that N-Boc-phthalimides 
21 and 22 could be separated more easily by column chromatography. Thus, the Boc 
derivatives were prepared from  17ab (Chart 2). The cyclodehydration of  17ab with 
TMAD and Bu3P in CH2Cl2 at 0 °C for 15 h followed by N-Boc-protection was carried 
out to produce a  3  : 1 mixture of 19a and 19b in 90% yield from  17ab. Debenzylation 
of  19ab using  H2/Pd-C and subsequent Mitsunobu phthaloylimination afforded crude 
phthalimides. After chromatographic separation of the trans-isomer 21 contaminated 
by diethyl  1,2-hydrazine-dicarboxylate formed in the Mitsunobu reaction, deprotection 
of the crude 21 with hydrazine hydrate and purification yielded (+)-1,  imifuramine,12) in 
37% overall yield  21) from the diol intermediate  17ab. Similarly,  cis-(+2  12) was 
obtained from crude 22 in 6% overall yield from  17ab. This synthetic process allows 
the synthesis of the enantiomer (-)-1 by simply switching the starting material to  (+)-12.
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 Synthesis of trans- and cis-Ethyl 4-(5-Hydroxymethylte-trahydrofuranyl) 
 imidazole-1-carboxylates Schunack et  al. used  3-(1H-imidazole-4-yl)propano1,22) 
 which is easily synthesized from urocanic acid, as the central building block to develop 
 many potent H3-agonists or  antagonists.23) Thus, trans- or  cis-alcohols 5 and 6 may be 
 useful intermediates to supply a variety of derivatives (Fig. 1). Since hydrogenolysis of 
 benzyl ethers  19ab or 23ab synthesized above afforded an inseparable mixture of the 
 corresponding alcohols, we intended an easy isolation of 5 and 6 by the cyclization of 
 a diol 29ab having a bulky trityloxy group at the C5'-position (Chart 3). 
  Novel  N[2-(trimethylsilyl)ethoxy]methyl (SEM) protected 4- and 5-iodoimidazoles 24 
 and 25 were first prepared from 4(5)-iodoimidazole  24,25) in 55% and 37% yields, 
 respectively (Chart 3, Eq. 1). The N-SEM compounds 24 and 25 were assigned by the 
 respective NOE experiments, as illustrated in Chart 3. According to the Lindell 
 procedure,26) 24 or 25 was treated with ethylmagnesium bromide to generate C4 or 
 C5-imidazole anions, which were then reacted with lactol 28,27) which was prepared by 
 reduction of  2,3-dideoxy-5-O-trityl-L-glyceropentanoic acid y-lactone 27) with DIBAL-H, 
to give the corresponding diols 26ab or 27ab in  81% and 56% yields, respectively 
 (Chart 3, Eq. 2). Thus, without heir isolation, the mixture of 24 and 25 was treated as 
 above to give an isomeric mixture (26ab, 27ab) in 78% yield (Chart 3). The following 
 cleavage of the SEM group with tetra-n-butyl ammonium fluoride sluggishly proceeded 
 in refluxing  THF to give unsubstituted imidazole 29ab  (41%), but this reaction was 
 improved to give a much higher yield (84%) under coexisting ethylenediamine 28) in 
 refluxing  THF for 20 h. Cyclization (TMAD-Bu3P) of 29ab in CH2Cl2, followed by 
 ethoxycarbonylation ofthe resulting  30ab produced trans- and cis-isomers 31 and 32 
after flash column chromatography. The better result [31 (43 %) and 32 (25%)] for the 
cyclization was attained in refluxing CH2Cl2 for 2 h in this case. Detritylation of 31 with 
 Pd(OH)2-C in cyclohexene gave the desirable (-)-5 (57%) and 
 4-(5-hydroxymethyltetrahydrofuranyl)-imidazole 33 (37%), the latter of which could 
 revert o 5 by  N-ethoxycarbonylation.122 In a similar manner,  cis-isomer (-)-6 (63%) and 
34 (25%) were obtained from 32. 
  Their configuration counterparts (+)-5 and (+)-6 were also synthesized from 
 2,3-dideoxy-5-O-trityl-D-glyceropen-tanoic cid  y-lactone  27) by the same methodology. 
The conversion of 5 or 6 into  trans-1 or its  cis-isomer 2 has already been described in 
our previous  report.12) Accordingly, the present method may become a more efficient 
stereodivergent synthetic route to the trans- and  cis-amino compounds than the 
previous method using the PhSe group. 
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(Eq. 1)
 (Eq.  2)
Chart 3
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Synthesis of  4(5)-[(2R,5S)-5-Aminomethyltetrahydrofu-ran-2-yl]imidazole [(+)-2] 
We reported an efficient and stereoselective synthesis of ethyl  4(5)-(2-deoxy-
13-ribofura-nosyl)  imidazole-1-carboxylate (35) by using the cyclization via a 
diazafulvene  intermediate.") An advantageous feature of this approach is that it 
enables the supply of a multigram scale of 35 from D-2-deoxyribose. Thus, we 
selected 35 for the synthesis of (+)-2 (Chart 4). 
 After phthaloylimination f 35, the deoxygenation of the resulting secondary alcohol 
36 was achieved as  follows.28) Reaction of 36 with  1,1'-thiocarbonyldiimidazole in DMF 
gave crude thiocarbonylimidazolide 37, which was subsequently treated with Bu3SnH 
and AIBN to give an ethoxycarbonyl compound 38 and unsubstituted imidazole 39 in 
42% and 30% yields from 36, respectively. We first encountered a low yield of 37, but 
the problem was solved by high concentration (1 M concentration of 36) of DMF. This 
result indicates the close contact of  1,1'-thiocarbonyldiimidazole and 36 in high 
concentration is essential to promote the reac-tion.  30) Deprotection of 38 and 39 with 
hydrazine hydrate afforded (+)-2 in 85% and 75% yields, respectively. In conclusion, 
we have described a simple and efficient synthesis of imifuramine (+)-1 and 
N-ethoxycarbonyl intermediates 5 and 6 via diazafulvene intermediates. Further, 
 (+)-cis-amino compound 2 was obtained from 35. The synthetic processes would 
supply a variety of derivatives by which the H4- receptor activities of tetrahydro 
furanylimidazoles can be assessed. 
Experimental 
 The melting points were determined on a hot-stage apparatus and were uncorrected. 
Optical rotation measurements were recorded with a JASCO DIP-1000 digital 
polarimeter.  IR spectra were recorded on a Shimadzu IR-435 spectrometer. 1H- and 
13C-NMR spectra were taken with tetramethylsilane as an internal standard on a 
Varian Gemini-200, Varian Mercury-300, and Varian UNITY INOVA-500 
spectrometers. Reactions with air- and moisture-sensitive compounds were carried 
out under an argon atmosphere. Unless otherwise noted, all extracts were dried over 
 Na2SO4, and the solvent was removed in a rotary evaporator under reduced pressure. 
Bu3P (>90%) was purchased from Tokyo Kasei Kogyou Co., Ltd. For column 
chromatography,  BW-127ZH, FL-60D, and Chromatorex NH-DM 1020 (Fuji Silysia 
Chemical Ltd.) were used.  THE was distilled from sodium-benzophenone. HPLC 
analyses were carried out with a Waters Associates instrument [column; Daicel 
CHIRALPAK ® AD, 0.46 cm X 25 cm; eluent, 10% 2-propanol in hexane; detection 254 
nm]. TLC were performed on pre-coated TLC plates with 60F 254 (silica gel, Merck). 
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 4(5)-R1RS,4R)-5-Benzyloxy-1,4-dihydroxypentyljimidazole  (17ab) A solution of 
 14ab (439 mg, 0.88 mmol) in  THF (10 ml) was refluxed with 1.5 N HCI (7 ml) for 4 h 
and then cooled. After neutralization by addition of 28% NH4OH, the solvent was 
evaporated to give a residue, which was extracted with  EtOAc (X3) by salting-out 
techniques. The extract was washed with brine, dried, and concentrated to give an oil, 
which was subjected to chromatography. Elution with  Me0H-EtOAc (3  : 7) afforded 
 17ab (231 mg, 95%) as a pale yellow oil. 1H-NMR (CDCI3) d: 1.30-2.12 (4H,m), 3.43 
(2H, d, J=7.6 Hz), 3.70-3.85  (1H, m), 4.54 (2H, s), 4.68  (1H, t, J=6.0 Hz), 6.96  (1H, s), 
 7.21-7.42 (5H, m), 7.62  (1H, s). 
tert-Butyl  4-[(2RS,5R)-5-Benzyloxymethyltetrahydrofuran-2-yl]imidazole-1- 
carboxylate  (19ab) To a solution of  17ab (1.058 g, 3.83 mmol) and Bu3P (1.52 ml, 
5.75 mmol) in CH2Cl2 (195 ml) at 0 °C was added TMAD (989 mg, 5.75  mmol). The 
resulting mixture was stirred at 0 °C for 15 h. The solvent was evaporated to give a 
residual oil, which was dissolved with CHCI3 and  H2O. The CHCI3 layer was washed 
with brine, dried, and concentrated to give a crude oil of  18ab. The solution of  18ab in 
 THF (8 ml) was stirred  with  Boc2O (1.671 g, 7.67 mmol) and Et3N (1.06 ml, 7.67  mmol) 
at room temperature (rt) for 22 h. The solvent was evaporated, and the residue was 
extracted twice with  EtOAc. The extract was washed with  H2O, brine, dried, and 
concentrated.  - The residual oil was subjected to flash chromatography using 
 EtOAc—hexane (1 : 4) for elution to  giVe  19ab [1.232 g (90%),  19a/19b = 3  :  1]. 
Although the separation of  19a (55%) and  19b (13%) was not required for the 
following experiment, 19a and 19b were carefully isolated by column chromatography 
by use of  EtOAc—hexane (3 : 7) and characterized spectroscopically. 19a: Colorless oil, 
 Rf  (ethyl acetate) 0.6.  IR (nujol) cm  21  :  1750. 1H-NMR (CDCI3, 300 MHz) d: 1.60 (9H, 
s), 1.77-1.97  (1H, m), 2.03-2.20 (2H, m), 2.24-2.40  (1H, m), 3.54 (2H, d, J=5.1 Hz), 
4.39  (1H, quint, J=5.7 Hz), 4.60 (2H, s), 5.04  (1H, t, J=6.2 Hz), 7.23-7.40 (6H, m), 8.00 
 (1H, s). HR-MS m/z: 358.1878 (Calcd for  C20F126N204 : 358.1891). El-MS m/z: 358 
 (Mt). 19b: Colorless oil; Rf (ethyl acetate) 0.55; IR (nujol) cm 21  :  1750. 1H-NMR 
 (CDCI3, 300 MHz) d: 1.60 (9H, s), 1.77-1.96  (1H, m), 1.98-2.16 (2H, m),  2.21-2.46  (1H, 
m), 3.48-3.64 (2H, m), 4.23  (1H, quint, J=5.9 Hz), 4.58 (2H, s), 4.95  (1H, t, J=6.2 Hz), 
7.23-7.40 (6H, m), 8.00  (1H, s). HR-MS m/z: 358.1878 (Calcd for  C20H26N204 
358.1891). El-MS m/z: 358 (Mt). 
Ethyl  4-(5-Benzyloxymethyltetrahydrofuran-2-yl)imidazole-1-car-boxylate (23ab) 
By the same procedure as for the preparation of  18ab, amixture of  17ab (130 mg, 0.47 
mmol), Bu3P (0.14 ml, 0.52 mmol), and TMAD (89 mg, 0.52 mmol) in benzene (15 ml) 
was stirred for 2 h at rt to give crude  18ab, which was refluxed with ethyl chloroformate 
(0.05 ml, 0.52 mmol), pyridine (0.04 ml, 0.52 mmol), and a catalytic amount of 
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 4-(dimethylamino) pyridine (DMAP) in benzene (20 ml) for 15  min to give a 2 : 1 
mixture (87 mg, 56%) of 23a and 23b as an oil: 1 H-NMR (CDCI3) d: 1.41 (3H, t, J=7.3 
Hz), 1.75-2.41 (4H,  m), 3.54 (4/3H, d,  J=5.0 Hz), 3.59 (2/3H, dd, J=5.0, 1.6 Hz), 
4.16-4.31 (1/3H, m), 4.32-4.55 (8/3H, m), 4.60 (2H, s), 4.98 (1/3H, t, J=6.4 Hz), 5.06 
(2/3H, t, J=6.4 Hz), 7.24-7.40 (6H, m), 8.10  (1H, s). 
tert-Butyl  4-[(2RS,5R)-5-Hydroxymethyltetrahydrofuran-2-yl]imidazole-l-
carboxylate  (20ab) A solution of  19ab (680 mg, 1.90 mmol) in  Me0H (20 ml) was 
hydrogenated over 10% Pd-C (408 mg) at 3.0 kg/cm 2 for 12 h. After filtration through 
Celite, the filtrate was concentrated to give a crude oil, which was purified by column 
chromatography  [MeOH—EtOAc  (3  : 97)] to give  20ab (421 mg, 83%) as a colorless oil. 
 IR (nujol) cm  21  :  1750. 1H-NMR  (CD3OD) d: 1.62 (9H, s), 1.76-1.92  (1H, m), 2.02-2.37 
(3H, m), 3.48-3.73 (2H, m), 4.05-4.16 (1/4H, m), 4.22 (3/4H, m), 4.84-5.02  (1H, 
overlapped with  H2O in  CD3OD), 7.62 (3/4H, s), 7.67 (1/4H, s), 8.17  (1H, s). HR-MS 
m/z: 269.1513 (Calcd for  C13H21N204  : 269.1500). SI-MS m/z: 269  (M+ +1). 
 4(5)-[(2R,5R)-5-Aminomethyltetrahydrofuran-2-yl]imidazole  [(+)-1] 
Phthalimide (440 mg, 2.99 mmol) and PPh3 (1.809 g, 6.90 mmol) were dissolved in a 
solution of  20ab (618 mg, 2.30 mmol) in  THE (13 ml). To this mixture was added 
DEAD (1.07 ml, 6.90 mmol) with stirring at 0°C. The reaction mixture was stirred at  rt 
for 1 h, and then the whole was concentrated to give a residue, which was 
subsequently dissolved in  EtOAc. The solution was washed with  H2O and brine, dried, 
and concentrated to give a crude oil, which was subjected to chromatography {Rf 
(80%  EtOAc in hexane); 0.68 (21), 0.62  (22)1. Elution with  EtOAc-hexane (19 : 31) 
afforded a mixture (1.1 g) of 21 and diethyl  1,2-hydrazinedicarboxylate. 21:  1H-NMR 
(CDCI3) d: 1.60 (9H, s), 1.75-1.90  (1H, m), 2.11-2.40 (3H, m), 3.68  (1H, dd, J=13.8, 5.0 
Hz), 3.89  (1H, dd, J=13.8, 8.2 Hz), 4.56  (1H, quint, J=6.5 Hz), 5.10  (11-1, t, J=6.3 Hz), 
7.24  (1H, s), 7.66-7.88 (4H, m), 7.99  (1H, s). 22:  1H-NMR (CDCI3) d: 1.60 (9H, s), 
1.74-1.94  (1H, m), 2.00-2.20 (3H, m), 3.80  (1H, dd,  J=13.3, 4.9 Hz), 3.95  (1H, dd, 
J=13.3, 7.4 Hz), 4.33-4.49  (1H, m), 4.98  (1H, t, J=6.2 Hz), 7.56  (1H, s), 7.66-7.92 (4H, 
m), 7.99  (1H, s). A solution of the crude 21 thus obtained and  NH2NH2-  H2O (813 mg, 
16.25 mmol) in EtOH (30 ml) was refluxed for 2 h and then cooled. A small amount of 
10% Pd-C was then added to the solution, and the reaction mixture was further 
refluxed for 10  min. After removal of the catalyst by filtration through a Celite pad, the 
solvent was evaporated to give a residual oil. It was purified by chromatography 
(Chromatorex NH-DM 1020) with  Me0H-EtOAc  (1  : 9) to give  (+)-1  12,21) (170 mg, 64% 
converted from a  3  : 1 mixture of 20a and 20b) as an oil: ORD (c=3.35,  EtOH) [a] (nm) 
17.8° (589),  111.1° (550),  116.1° (500), 122.2° (450), 138.2° (400), 173.0° (350). 
 1H-NMR  (CD3OD) d: 1.61-1.82 (1H, m), 2.02-2.38 (3H, m), 2.73 (2H, d,  J=6.0 Hz), 
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 4.17  (1H, m), 5.02  (1H,  t,  J=6.5 Hz), 7.02  (1H, s),  7.64  (1H, s). 
4- and  5-lodo-1-[2-(trimethylsilyl)ethoxymethyl]-11-1-imidazole (24, 25) A 
suspension of NaH (60% in mineral oil, 134 mg, 3.30 mmol) in hexane was stirred for 5 
 min. After removal of the supernatant solution,  THF (4 ml) was added  therein. A 
solution of  4(5)-iodoimidazole  24,25) (582 mg, July 2003 835 Chart 4.3.00 mmol) in  THE 
(3 ml) was added to the resulting suspension of NaH at 0  °C. The whole was stirred for 
0.5 h at rt, and then  2-(trimethylsilyl)-ethoxymethyl c loride (0.60 ml, 3.15 mmol) was 
added to the mixture at 0  °C. After 15  min at the same temperature, the reaction was 
quenched with saturated  NH4CI solution and the  THF was concentrated. The residue 
was extracted twice with  CH2Cl2  , and the solution was subsequently washed with  H2O, 
brine, dried, and concentrated to give a crude oil. Chromatography using  EtOAc and 
hexane  (1  : 3) as eluent gave 24 (535 mg, 55%) and 25 (362 mg, 37%). 24: Colorless 
oil,  1H-NMR (CDCI3) d: 0-0.10 (9H, m), 0.92 (2H, t, J=8.0 Hz), 3.49 (2H, t, J=8.0 Hz), 
5.26 (2H, s), 7.15  (1H, s), 7.50  (1H, s). 13C-NMR (CDCI3) d: 20.9, 18.1, 66.8, 76.0, 
124.1, 138.2. HR-MS m/z: 324.0158 (Calcd for  C91-1171N20Si: 324.0156). El-MS  m/z: 
324 (M  1  ). 25: Colorless oil, 1H-NMR (CDCI3) d: 0-0.16 (9H, m), 0.93 (2H, t, J=8.0 Hz), 
3.54 (2H, t, J=8.0 Hz), 5.28 (2H, s), 7.15  (1H, s), 7.75  (1H, s). 13C-NMR (CDCI3) d: 
20.9, 18.1, 66.5, 76.0, 137.0, 139.8. HR-MS m/z: 324.0156 (Calcd for  C91-1171N20Si: 
324.0156). El-MS m/z: 324  (M+). 
 1-(2-Trimethylsilyl)ethoxymethyl-4-[(  iRS,4R)-1,4-dihydroxy-5-trity-loxypentyl]im 
idazole (26ab) A solution of 24 (925 mg, 2.86 mmol) in dry CH2Cl2 (11 ml) was added 
to a 3  M Et20 solution of EtMgBr (0.95 ml, 2.86 mmol) at 0 °C. After 40  min at rt,  28  27) 
(411 mg, 1.14 mmol) in dry CH2Cl2 (2.5 ml) was added dropwise at 0 °C, and the 
mixture was stirred at rt for 14 h. Saturated  NH4CI solution was then added, and the 
aqueous phase was extracted twice with CH2Cl2. The combined organic extracts were 
washed with  H2O, dried  (MgSO4) and concentrated. Flash chromatography of the 
residue yielded 26ab (517 mg, 81%) as a colorless oil. 1H-NMR  (CD3OD) d: 20.03 
(9/2H, s), 0.01 (9/2H, s), 0.85 (2H, t, J=9.4 Hz), 1.25-2.08 (4H, m), 2.90-3.14 (2H, m), 
3.50 (2H, t, J=9.4 Hz), 3.74  (1H, m), 4.60  (1H, t,  J=6.3 Hz), 5.38 (2H, s), 7.09  (1H, s), 
7.13-7.50 (15H, m), 7.71  (1H, s). HR-MS m/z: 559.2992 (Calcd for  C33H43N204 Si:
559.2990). SI-MS m/z: 559  (M+ +1). 
 1-(2-Trimethylsilyl)ethoxymethy1-54(  /RS,4R)-1,4-dihydroxy-5-trityl-oxypentyl]im 
idazole (27ab) In the same manner as 26ab, a solution of  28  27) (443 mg, 1.23 mmol) 
in CH2Cl2 (2 ml) was added to a mixture of 25 (997 mg, 3.01 mmol) and 3  M Et20 
solution of EtMgBr (1.00 ml, 3.00 mmol) to give 27ab (387 mg, 56%) as a colorless oil. 
1H-NMR  (CD3OD) d: 0.00 (9H, s), 0.86 (2H, t, J=8.0 Hz), 1.37-2.12 (4H, m), 2.95-3.18 
                          25
(2H, m), 3.44-3.59 (2H, m), 3.70-3.84  (1H,  m), 4.77  (1H, t, J=7.2 Hz), 5.28-5.59 (2H, 
m), 6.92  (1H, s), 7.16-7.53 (15H, m), 7.76  (1H, s). HR-MS m/z: 559.2991 (Calcd for 
 C33H43N204 Si: 559.2990). SI-MS m/z: 559  (M+ +1). 
 1-(2-Trimethylsilypethoxymethy1-4(5)-MRS,4R)-1,4-dihydroxy-5-trityloxypentylji 
midazole (26ab/27ab) By the same procedure as for the preparation of 26ab, a  1  : 1 
mixture (2.309 g, 7.13 mmol) of 24 and 25 in dry  CH2Cl2 (29 ml) was added to a 3  M 
Et20 solution of  EtMgBr (2.38 ml, 7.13 mmol) at  0  °C. After 0.5 h at rt,  28  27) (1.026 g, 
2.85 mmol) in dry CH2Cl2 (6 ml) was added at 0 °C, and the mixture was stirred at rt for 
14 h followed by column chromatography to yield a  3.6  : 1 mixture of 26ab and 27ab 
(1.243 g, 78%) as an oil. 
 4(5)-[(1RS,4R)-1,4-Dihydroxy-5-trityloxypentyl]imidazole (29ab) To a solution of 
26ab/27ab (200 mg, 0.36  mmol) in  THF (1.5 ml) 1  M  THF solution of 
tetra-n-butylammonium fluoride (1.08 ml, 1.07 mmol) and ethylenediamine (0.14 ml, 
2.15 mmol) were added, and the resulting mixture was refluxed for 20 h. A small 
amount of silica gel was added to the cooled solution. The solvent was evaporated to 
give a coated silica gel, which was subsequently placed in a column. Chromatography 
using  Me0H—Et0Ac  (1  : 9) gave 29ab (129 mg, 84%) as white amorphous product. 1 
H-NMR  (CD30D) d: 1.28-2.04 (4H, m),  2.91-3.15 (2H, m), 3.64-3.80  (1H, m), 4.66  (1H, 
t, J=6.4 Hz), 6.97  (1H, s), 7.12-7.51 (15H, m), 7.70  (1H, s). HR-MS m/z: 429.2199 
(Calcd for  C27H28N203 : 429.2176). SI-MS m/z: 429  (M+ +1). 
Ethyl  4-[(2R,5R)-(5-Trityloxymethyl)tetrahydrofuran-2-yl]imidazole-1-carboxylate 
(31) and Its 2S,5R-Isomer (32) To a solution of 29ab (320 mg, 0.75 mmol) in  CH2Cl2 
(25 ml) were added Bu3P (0.31 ml, 1.12 ml) and TMAD (193 mg, 1.12 ml). The mixture 
was refluxed for 2 h and then washed with H20, dried  (MgSO4), and evaporated to 
give a crude oil of  30ab. A solution of the crude  30ab, ethyl chloroformate (0.14 ml, 
1.50 mmol), pyridine (0.12 ml, 1.50 mmol), and DMAP (10 mg) in benzene (2.5 ml) 
was stirred at rt for 1 h. After addition of H20, the solvent was evaporated and the 
residue was extracted twice with  EtOAc-hexane  (2  : 1). The extract was washed with 
H20, dried, and concentrated. The residual oil was purified by flash column 
chromatography using  EtOAc-hexane (3 : 7) for elution to give  31  (153 mg, 43%), and 
then 32 (91 mg, 25%). (+)-31: Color-less oil, Rf (50%  EtOAc in hexane); 0.47. IR 
(nujol) cm  21  :  1755.  MD  5121.9° (c=3.57,  Me0H). 1H-NMR  (CDCI3) d: 1.42 (3H, t, 
J=7.1 Hz), 1.82-1.93  (1H, m), 2.04-2.21 (2H, m), 2.23-2.38  (1H, m), 3.11  (1H, dd, 
J=9.6, 5.1 Hz), 3.19  (1H, dd, J=9.6, 5.1 Hz), 4.38-4.49 (3H, m), 5.04  (1H, t, J=6.3 Hz), 
7.16-7.53 (16H, m), 8.09 (1H, s). 13C-NMR (CDCI3) d:  14.6,  29.0,  32.1,  64.4,  66.4, 75.3, 
78.4, 113.1, 126.5, 127.3, 128.3, 136.6, 143.6, 145.0, 148.1. HR-MS m/z: 482.2199 
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(Calcd for  C30H30N204 : 82.2204). El-MS m/z: 482  (M+). (+)-32: Colorless oil,  Rf  (50% 
 EtOAc  in hexane) 0.40.  [a]c,  5118.3° (c=3.60,  Me0H). IR (nujol) cm  21  :  1755. 1H-NMR 
(CDCI3) d: 1.35 (3H, t, J=7.1 Hz), 1.77-1.92  (1H, m), 1.95-2.14 (2H, m), 2.21-2.35  (1H, 
m), 3.14  (1H, dd, J=9.6, 4.5 Hz), 3.27  (1H, dd, J59.6, 5.4 Hz), 4.23  (1H, m), 4.33-4.49 
(2H, m), 5.00  (1H, t,  J=6.1 Hz), 7.17-7.51 (16H, m), 8.06  (1H, s).  13C-NMR (CDCI3) d: 
 14.5,  28.5,  31.9,  64.3,  66.5,  76.0,  79.1,  113.0,  126.5, 127.3, 128.3, 136.4,  143.6,  145.5, 
148.0. HR-MS m/z: 482.2208 (Calcd for  C30H30N204 : 82.2204). El-MS m/z: 482  (M+). 
The configuration counterparts (-)-31 and (-)-32 were synthesized by the present 
method from L-glutamic acid. (-)-31:  [4)  5220.1° (c=1.80,  Me0H),  (-)-32:  [a])  5217.3° 
 (c=1.92,  Me0H). 
 (-)-Ethyl  4-[(2R,5R)-5-Hydroxymethyltetrahydrofuran-2-yl]imidazole-1- 
carboxylate [(-)-5] A mixture of  31  (126 mg, 0.26 mmol), 20% Pd(OH)2-C (76 mg), 
and cyclohexene (0.79 ml, 7.83 mmol) was refluxed for 2.5 h. After filtration through a 
Celite pad, the filtrate was concentrated to give a residue. It was purified by column 
chromatography using  Me0H—EtOAc (1  :  19) to give (-)-5  12) (36 mg, 57%) as a 
colorless oil. Further elution with  Me0H provided 33 (16 mg, 37%) as an oil, which was 
subsequently reverted to (-)-5 (53%) by treatment with ethyl  chioroformate and 
 DMAP.12) (-)-5: Rf  (10%  Me0H in  EtOAc); 0.42.  1H-NMR  (CD3OD) d: 1.41 (3H, t, J=6.9 
Hz), 1.77-1.89  (1H, m), 1.97-2.16 (2H, m), 2.22-2.36  (1H, m), 3.53  (1H, dd, J=11.0, 5.1 
Hz), 3.60  (1H, dd, J=11.0, 4.2 Hz), 4.22  (1H, quint, J55.5 Hz), 4.47 (2H, q,  J=6.9 Hz), 
4.98  (1H, t, J=6.5 Hz), 7.46  (1H, s), 8.22  (1H, s). 33:  1H-NMR  (CD3OD) d: 1.76-1.92 
 (1H, m), 1.96-2.19 (2H, m), 2.24-2.42  (1H, m), 3.54  (1H, dd, J=11.8, 5.4 Hz),3.62  (1H, 
dd, J=11.8, 3.7 Hz), 4.17-4.27  (1H, m), 5.09  (1H, t, J=6.9 Hz), 7.30  (1H, s), 8.38  (1H, 
s). The configuration counterpart (+)-5 was synthesized by the present method from 
L-glutamic acid. (+)-5:  [a]c, 513.20° (c=1.97, CHCI  3  ).31) HPLC (flow rate 2  ml/min;  t R 
15.6  min) exhibited a single peak. 
 (-)-Ethy14-[(2  S,5R)-5-Hyd  roxymethyltetrahyd  rof  u  ran-2-yl]  m  dazo  le-1-carboxyl  at 
e  [(-)-6] The mixture of 32 (70 mg, 0.15 mmol), cyclohexene (0.44 ml, 4.35 mmol), and 
20% Pd(OH)2-C (42 mg) in  EtOH (4 ml) was refluxed to give (-)-6 12) (22 mg, 63%) and 
34 (6 mg, 25%) as colorless oils by the same procedure for the preparation for 5. (-)-6: 
Rf  (10%  Me0H in  EtOAc); 0.33.  1H-NMR  (CD3OD) d: 1.41 (3H, t, J=7.1 Hz), 1.77-2.11 
(3H, m), 2.14-2.35  (1H, m), 3.55  (1H, dd,  J=11.9, 5.3 Hz), 3.67  (1H, dd,  J=11.9, 3.9 
Hz), 4.10  (1H, quint, J=5.7 Hz), 4.48 (2H, q,  J=7.1 Hz), 4.84-4.94  (1H, m, overlapped 
with  H2O in  CD3OD), 7.52  (1H, s), 8.23  (1H, s). 34: 1 H-NMR  (CD3OD) d: 1.80-2.14 
(3H, m), 2.20-2.36  (1H, m), 3.57  (1H, dd, J=11.7, 5.0 Hz), 3.70  (1H, dd, J=11.7, 3.6 
Hz), 4.06-4.18  (1H, m), 5.00  (1H, t, J=6.6 Hz), 7.23  (1H, s), 8.20  (1H, s). The 
configuration counterparts were synthesized by the present method from L-glutamic 
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acid. (+)-6:  [a]c.  519.78° (c=1.64,  CHCI3).31) HPLC (flow rate 2  ml/min; t R 10.4  min) 
exhibited a single peak. 
Ethyl  4-(2,5-Dideoxy-5-phthaloylamino-f3-ribofuranosyl)imidazole-1-carboxylate 
(36) Phthalimide (828 mg, 5.63 mmol) and PPh3 (1.48 g, 5.63 mmol) were dissolved in 
a solution of 35 (1.31 g, 5.12 mmol) in  THF (70 ml). To this mixture was added DEAD 
(0.96 ml, 5.63 mmol) with stirring. The reaction mixture was stirred at rt for 2 h, and 
then the  THF was evaporated to give a residue. It was purified by flash 
chromatography with  EtOAc—hexane (11 : 9) to give 36 (1.795 g, 95%) as a white 
amorphous product. IR (KBr) cm  21  :  3400, 1762, 1712. 1H-NMR (CDCI3) d: 1.43 (3H, 
 t,  J=7.0 Hz), 2.30 (2H, dd, J=7.0, 4.5 Hz), 3.00  (1H,  br  s), 3.88 (2H, m), 4.18  (1H, m), 
4.45 (3H, m), 5.16  (1H,  t,  J=7.0 Hz), 7.38  (1H, s), 7.64-7.75 (2H, m), 7.78-7.89 (2H, m), 
8.00  (1H, s). 13C-NMR (CDCI3) d:  14.7,  40.6,  40.8,  64.9,  74.6,  74.9,  84.2, 114.4, 123.8, 
132.5, 134.5, 137.5, 144.8, 149.0, 169.0. HR-MS m/z:  386.1352 (Calcd for 
 C19H20N306  : 386.1351). SI-MS m/z: 386  (M+ +1). 
Deoxygenation of 36 A mixture of 36 (237 mg, 0.615 mmol) and 
thiocarbonyldiimidazole (135 mg, 0.737 mmol) in DMF (0.6 ml) was stirred at rt for 13 h. 
The resulting mixture was dissolved with  EtOAc, and the solution was washed with H 2 
 0 and brine, dried, and concentrated to give a crude 37. To a toluene solution (15 ml) 
of the crude 37 were added a mixture of Bu3SnH (0.20 ml, 0.74 mmol) and AIBN (10 
mg, 0.06 mmol) in toluene (0.5 ml), and then the whole was refluxed for 0.5 h. 
Evaporation of the solvent afforded a residual oil, which was subsequently dissolved 
with CH3CN. The solution was washed with hexane and evaporated to give a residue. 
Flash chromatography using  EtOAc-hexane (1 : 1) as eluent gave ethyl  4- 
[(2R,5S)-5-phthaloylaminotetrahydrofuran-2-yl]imidazole-1-carboxylate 38 12) (96 mg, 
42%) as a white solid. Further elution with  EtOAc—MeOH. (97 : 3) provided 
 4(5)-R2R,5S)-5-phthaloylaminotetrahydrofuran-2-Aimidazole 39 12) (56 mg,30%) as 
an amorphous product. 38: IR (KBr) cm  21  :  1760 1722.  'H-NMR (CDCI3) d: 1.45 (3H, t, 
J=7.3 Hz), 1.73-1.94  (1H, m), 2.00-2.22 (2H, m), 2.22-2.40  (1H, m), 3.81  (1H, dd, 
J=14.1, 5.6 Hz), 3.94  (1H, dd, J=14.1, 5.6 Hz), 4.38  (1H, td, J=7.0, 5.6 Hz), 4.47 (2H, q, 
J=7.3 Hz), 4.97  (1H, dd, J=4.7, 3.7 Hz), 7.54  (1H, s), 7.70-7.73 (2H, m), 7.84-7.88 (2H, 
m), 8.03  (1H, s). HR-MS m/z: 369.1320 (Calcd for  C19H19N305  :  369.1323). El-MS m/z: 
369  (M+). 39: 1H-NMR (CDCI3) d: 1.74-1.84  (1H, m),  2.01-2.18 (3H, m), 3.75-3.83 (2H, 
m), 4.37-4.44  (1H, m), 5.11  (1H, dd, J=5.1, 3.6 Hz), 6.94  (1H, s), 7.11  (1H, s), 
7.69-7.79 (2H, m),  7.81-7.93 (2H, m). Although the separation of 37 was not required 
for the following experiment, it could be isolated as a white solid by use of 
 Me0H—CHCI3  (1  : 100) as eluent: mp 176-178 °C. IR (KBr) cm  21  :  1760, 1710. 1 
H-NMR (CDCI3) d: 1.46 (3H, t, J=7.5 Hz), 2.65 (2H, m), 3.99 (2H, d, J=7.5 Hz), 4.49 
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 (2H, q, J=7.5 Hz), 4.60  (1H, t, J=7.5 Hz), 5.26  (1H, dd, J=9.8, 6.9 Hz), 6.00  (1H, d, 
J=3.9 Hz), 7.02  (1H, s), 7.46  (1H, s), 7.55  (1H, s), 7.75 (2H, m), 7.87 (2H, m), 8.09  (1H, 
s), 8.28  (1H, s). HR-MS m/z: 496.1287 (Calcd for  C23H22N506S: 496.1289). SI-MS 
m/z: 496  (M+ +1). 
 (+)-4(5)-R2R,5S)-5-Aminomethyltetrahydrofuranyljimidazole [(+)-2] 
By the same procedure for the preparation of (+)-1, a solution of 38 (382 mg, 1.04 
mmol) and hydrazine hydrate (0.25 ml, 5.18 mmol) in  EtOH (20 ml) was refluxed for 1 
h to yield  (+)-2 (147 mg,  85%) as an oil. Similarly, 41 (149 mg, 0.50  mmol) was 
converted into (+)-2 (63 mg, 75%) as an oil.  [a]p  5127.0° (c=3.40,  Me0H). IR (film) cm 
 21  :  3700-2200, 1038. 1H-NMR (CDCI3) d: 1.70-1.92  (1H, m), 1.96-2.33 (3H, m), 2.72 
 (1H, dd, J=12.2, 7.0 Hz), 2.80  (1H, dd, J=12.2, 5.2 Hz),  4.03  (1H, ddd, J=12.2, 7.0, 5.2 
Hz), 4.94 (overlapped with  H2O in  CD3OD), 7.03  (1H, s), 7.65  (1H, s). HR-MS m/z: 
168.1134 (Calcd for  C8F114N30: 168.1136). SI-MS m/z: 168  (M+ +1). 
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Abstract 
 The histamine H3- receptor exists on the nerve endings in the central and peripheral 
nervous systems, and regulates not only the synthesis and release of histamine as an 
auto-receptor, but also the release of other neurotransmitters a  a hetero-receptor. It 
has been postulated that the histamine H3- receptor might be involved in various 
neurological disorders, such as migraine, attention-deficit  / hyperactivity disorder 
(ADHD), epilepsy, narcolepsy, and neurogenic inflammation. 
 We previously synthesized respective stereoisomers of tetrahydrofuranylimidazoles 
and examined their activities on histamine H3- receptor using an in vivo assay (rat 
brain microdialysis) and an in vitro assay (electrically evoked contractions of guinea 
pig ileum). These compounds spatially arrange the imidazole and side chain on the 
 THE ring. Among them,  (+)-4(5)-[(2R,5R)-5-aminomethyltetrahydrofuran-2-yl] 
imidazole [imifuramine,  (+)-2] was the eutomer exhibiting high H3- agonistic activity on 
the rat brain and its enantiomer [(-)-2] was an antagonist on the guinea pig ileum. 
Replacement of the amino group of imifuramine by cyanoguanidine moiety did not 
hamper the H3- activities on the two assays.  Moreover, incorporation of amino group at 
the 3- or 4-position of the  THE ring almost resulted in decrease of the activity, although 
compounds (+)-6, (-)-6 and (+)-8 exhibited relatively high antagonistic activity on the 
guinea pig ileum. The present results suggest that the stereochemistry of the 
tetrahydrofuranylimidazoles is useful for the investigation of selective ligands for  H3-
receptor, and that the trans-forms of respective stereoisomers preferentially exhibited 
H3- receptor activities. 
                           32
Introduction 
 The histamine H3- receptor has been originally discovered in the brain in 1983 by 
Arrang and  coworkers.' This receptor  described to be located presynaptically on the 
histaminergic nerve endings, regulating the synthesis and release of histamine by a 
negative feedback as a presynaptic  autoreceptor.' Later, the function of the receptor 
was found not only to inhibit he synthesis and release of  histamine,43 but also to play 
an important regulatory role in the release of other neurotransmitters uch as 
noradrenaline acetylcholine, dopamine, 5-hydroxy-tryptamine as a heteroreceptor in 
the central nervous  system4-11 and in the peripheral sites such as the cardiovascular, 
respiratory and gastrointestinal  systems.12-14 Recently, the histamine H3- receptor has 
become of great interest for their possible involvement in a variety of physiological and 
pathophysiological processes. After extensive in vitro and in  vivo research, it has been 
postulated that the histamine H3-receptor might be involved in various neurological 
disorders, such as migraine,  attention-deficit  / hyperactivity disorder (ADHD), epilepsy, 
narcolepsy, and neurogenic  inflammation.1517 
 (R)-a-methylhistamine and thioperamide were the first H3- receptor ligands 
synthesized as selective full agonist and competitive antagonist,  respectively.'  8-20 After 
that, many compounds targeted the histamine H3- receptor has been developed.21 In 
previous study, our group synthesized four stereoisomers of novel imidazole 
 C-nucleoside  (ICN) derivatives, which combined amino group opposite imidazole ring 
on the tetrahydrofuran (THF), and tested for activities on H3- receptors by functional 
bioassay using an in vivo intracerebral brain microdialysis method. Among them, only 
(+)-4(5)-[(2R,5R)-5-(aminomethyl)THF-2-yl] imidazole  (Imifuramine) exhibited 
agonistic activity approximately equal to that of immepip.22'23 Whereas the other 
 stereoisomers were inactive.22 
 To investigate the effects of the replacement of the amino group by a 
cyanoguanidine moiety and the intramolecular hydrogen-bonding interaction between 
the amino group and the  Nx- imidazole ring nitrogen (N-adjacent o the side chain) on 
the potency at the histamine H3- receptor, we have prepared a series of imifuramine 
chiral analogs (Table). The H3- activity of these compounds was determined both by 
an in vivo intracerebral microdialysis method and an in vitro Magnus method using the 
isolated guinea-pig ileum segment. 
Material and methods 
Drugs 
 Histamine dihydrochloride and mepyramine maleate were purchased from Sigma 
Chemicals (St. Louis, MO, USA). Thioperamide was kindly donated by Dr. J. C. 
Schwartz (Unite de Neurobiology, Center Paul Broca de  I'INSERM, Paris, France). 
(R)-a-methylhistamine was synthesized by Dr. Harusawa (Osaka, Japan). 
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in vivo microdialysis 
 MaleWistar rats weighing about 250 g were anesthetized with urethane (1.2 g/kg, 
i.p.) and placed in a stereotaxic apparatus. A dialysis probe was inserted into the 
anterior hypothalamic area (AHy) with coordinates of  AP:1.5,  L:0.5, V:9.2 mm relative 
to the bregma. The AHy was perfused with artificial cerebrospinal fluid (CSF), 
containing 140 mM  NaCI, 3 mM KCI, 2.5 mM  CaCl2, 1 mM  MgCl2 and 5 mM glucose, 
pH 7.4, through a dialysis probe at 1  pl/min. Two hours after the insertion of a probe, 
samples were collected every 20  min and frozen immediately at -40 °C until analysis. 
Test compounds were added to CSF at the concentration of 10 pM, and administered 
through the dialysis membrane. The concentration of histamine in the dialysate was 
assayed by  HPLC.24'26 
in vitro Magnus method 
 Male Hartley strain guinea pigs weighing between 350 and 400 g were killed by 
decapitation. The ileum including the longitudinal muscle-myenteric plexus was 
dissected in Krebs solution maintained at 37 °C bubbled with 02 / CO2 (95% : 5%). 
The ileum preparation was hung into an organ bath (10 ml) and its isometric 
contraction was measured using a transducer equipped with a data recorder. Single 
square-wave pulses (0.5 msec, 5V to 8V, 0.1 Hz) were delivered by an electrical field 
stimulator. The experiments were performed in the presence of 0.1 pM  mepyramine.26 
• Results and Discussion 
 In the microdialysis method, four stereoisomers (3 - 4) in which the amino group of 
imifuramine was substituted by the  cyanoguanidine moiety, exhibited H3 antagonist 
property (Table). All compounds incorporating the amino group at the 3- or 4-position 
of the tetrahydrofuran (5 - 7) did not affect the histamine release (Table). On the other 
hand, in the Magnus method, the compounds (-)-2, (-)-3, (+)-3, (-)-4, (+)-5, (-)-6, (+)-6 
and (+)-8 antagonized  R-(a)-methylhistamine induced suppression of the ileum 
contraction (Fig. 1 and Table). 
 These results indicated that 1) replacement of the amino group by a cyanoguanidine 
moiety in all four imifuramine stereoisomers exhibited antagonistic activity in both in 
vivo and in vitro assays except for (+)-4, 2) compounds (+)-5 and (+)-8 exhibited a 
surprising discrepancy between in vivo and in vitro activities. 
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• (R)-a-Methylhistamine 
 o  +  10-6  M (-)-2 
•  +  10-5  M (-)-2 
 o +  10-4 M (-)-2
log [(R)-a-Methylhistamine]
Fig. 1 Concentration-response curves of (R)-a-methylhistamine onelectrically stimulated 
guinea pig ileum. 
(R)-a-methylhistamine could  effectively reduce the contractions and this effect was blocked 
competitively by (-)-2.
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Table in vivo and in vitro activities of several analogues of imifuramine and its 
stereoisomers for histamine H3- receptor. Results are presented as average values of 
at least triplicate determinations.
No. configuration
H
N
i
__
kN 0 5 R3
23 c
4
 Ri R2
Rata pA2b (pD2b)
R2 R3
(-)-1 2S, 5R -H -H -CH2NH2
(+)-1 2R, 5S -H -H -CH2NH2
(-)-2 2S, 5S -H -H -CH2NH2 6.09
 (+)-2
imifuramine
2R, 5R -H -H -CH2NH2 agonist (3.93)
 (-)-3 2S, 5R -H -H -A antagonist 5.29
(+)-3 2R, 5S -H -H -A antagonist 6.06
 (-)-4 2R, 5R -H -H -A antagonist 6.19
(+)-4 2S, 5S -H -H -A antagonist  _C
 (-)-5 2R, 3R -NH2 -H -H
(+)-5 2S, 3S -NH2 -H -H 5.58
(-)-6 2S, 4S -H -NH2 -H  N.D.  d 6.70
(+)-6 2R, 4R -H -NH2 -H  N.D.  d  6.69
(+7 2R, 4S -H -NH2 -H
(+)-7 2S, 4R -H -NH2 -H
(+)-8 2S, 4R -H -B -H C 6.71
a Effect after administration of 10 pM using in vivo rat brain mi
crodialysis 
b Electrically evoked contractions of guinea-pig ileum 
- = not active; d n.d. = not determined
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Abstract 
 A series of sixteen compounds related to chiral 4(5)-(5-aminomethyltetrahydro 
furan-2-yl)imidazoles (1) have been designed, synthesized, and examined in vitro by 
radioligand displacement studies and functional assays for both the human H3- and 
H4- receptors expressed in SK-N-MC cells. Among them, the (2S,5S)-isomer  1d of 
amino compounds showed approximately 300-fold higher selectivity at the  H3-
receptor than the H4- receptor. On the other hand, (2R,5S)- and  (2R,5R)- 
cyanoguanidines 3b and 3c, in which the amino group of the compounds  1  b and  lc 
was substituted by the cyanoguanidino moiety, bound to the H4- receptor with a  pEC50 
value of 6.65 and 7.11, respectively, and had >40-fold selectivities over the  H3-
receptor. As such, 3b and 3c are the first selective H4- receptor agonists. 
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Introduction 
 A new histamine receptor, H4- receptor, was discovered by several groups in the 
quest for new G-protein-coupled-receptors  (GPCR).1-6 The overall amino acid 
sequence showed approximately 37% homology between H3- and H4- receptors. 
However, the distribution of the human H4- receptor mRNA was entirely different from 
that of the H3-  receptor:1'6-8 Although little is known about its function in vivo, its 
expression in the bone marrow and eosinophils may elucidate a potential new role for 
histamine in the regulation of hemopoietic and immune functions.1'3 To investigate the 
possible physiological function of the receptor, a specific ligand is required. Yet, most 
H3- receptor ligands are active at the H4- receptor as well. For example, the classical 
"selective" H
3- receptor agonist, (R)-a-methylhistamine shows H4- agonistic activity, 
and thioperamide, the H3- antagonist prototype, has moderate affinities for the  H4- 
receptor.1 No  ligands have so far been reported that can selectively target the human 
H4- receptor. 
 In our previous study, we synthesized the respective four  stereoisomers of the
tetrahydrofurans  (THFs) and dihydrofurans 
 (DHFs) containing imidazole and 
examined their H3- receptor pharmacology 
using the in vivo microdialysis method in 
rats. These compounds spatially arrange 
the imidazole and aminomethyl groups 
across the  THE and DHF rings (Figure 1). 
Among them, Only  (+)-4(5)-[(2R,5R)-5- 
aminomethyltetrahydrofuran-2-yl]imidazole 
(imifuramine,  1c) was the eutomer 
exhibiting H3-agonistic  activity.9.1° 
 In this study, we examined the binding 
affinity and functional activity for the human 
H3- (hH3-) and H4- (hH4-) receptors of a 
total of sixteen tetrahydrofuranyl 
imidazoles: THFs (Figure 1-A), DHFs 
(Figure 1-B), and newly synthesized 
cyanoguanidines (Figure 2-A) and 
benzylethers (Figure 2-B).
Figure 1.
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Results 
 The competitive binding affinities  (pKi  value) for the hH3- receptor of the DHFs (2a, 
2b, 2c, and 2d) and cyanoguanidines (3a,  3b, 3c, and 3d) were significantly lower 
than that of the  THFs  (la,  lb,  lc, and  1d) and benzylethers (4a, 4b, 4c, and 4d) 
(Table 1). The  pKi  values of  1c,  ld, 4b, and 4c for the binding to the hH3- receptor 
were 10-fold higher than that of the other compounds, and were 6.64 ± 0.12, 6.66 ± 
0.14, 6.48 ± 0.16, and 6.61 ± 0.14, respectively. The trans-isomers  (1c,  ld, 2c, and 
2d) of amino compounds (THFs and DHFs) exhibited about 10-fold higher affinity than 
their cis-isomers  (la,  lb, 2a, and 2b). In a functional H3- receptor assay, the 
compounds  la,  lb,  lc,  ld, 2b, 2c, 4b, and 4c acted as full agonists (0.9 < a < 1.0, 
Table 1). Among them,  1c had the highest agonistic activity. 
 As shown in Table 2,  1c, 3b, 3c, and 4b competed for  [31-1] histamine binding to the 
hH4-receptor with  pKi  values of 6.05 ± 0.04,  6.65  ± 0.06, 6.90 ± 0.17 and 6.36 ± 0.11, 
respectively. Moreover, the six compounds,  la, 3a, 3b, 3c, 3d and 4b, all showed 
agonist properties with high intrinsic activities (0.9  <  a < 1.0). Among them, 3c most 
potently inhibited the 1  !AM forskolin-stimulated responses with an apparent  pEC5o 
value of 7.11 ± 0.05 (Table 2). A
Figure 2.11
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Table 1. pEC50 values and affinity values of tetrahydrofuranylimidazoles for the human 
H3-receptor 
The  pEC50 values were determined by the inhibition of the forskolin-stimulated (1  pM) 
cAMP production, expressing the human H3- receptor. All values shown are means ± 
S.E.M. of at least four experiments. H3- receptor competition binding was performed 
using  [3H]  Na-methylhistamine (1nM).
Compounds Configuration
Functional activity Binding
 pEC50 Efficacy (a) pKi
Histamine 8.39 ± 0.06 1.00 7.47  ± 0.11
(R)-a-Methylhistamine 9.91 ± 0.05 0.85 ± 0.05
 la 2S,5R 6.09 ± 0.05 0.95 ± 0.04 5.77  1 0.03
 1b 2R,5S 6.11 ± 0.08 1.06 ± 0.04 5.69  ± 0.05
 lc [Imifuramine] 2R,5R 7.35 ± 0.07 1.04  ±  0.05 6.64  ± 0.12
 1d 2S,5S 6.98  ± 0.05 0.91 ± 0.04 6.66  1 0.14
2a 2S,5R  <4  4.70  ± 0.20
2b 2R,5S 4.57 ± 0.15 0.93 ± 0.06 4.94  ± 0.08
2c 2R,5R 6.57 ± 0.10 1.00 ± 0.05 5.99  -1 0.10
2d 2S,5S 5.55 ± 0.13 0.75 ± 0.06 5.60  -1 0.09
3a 2S,5R NE  <  0.1 5.09  ± 0.08
3b 2R,5S 4.99  ± 0.08 0.43 ± 0.03 5.15  ± 0.17
3c [OUP-16] 2R,5R 5.50 ± 0.08 0.79 ± 0.06 5.66  ± 0.09
3d 2S,5S  <4 4.73  ± 0.13
 4a 2S,5R 5.01 ± 0.07 0.86 ± 0.04 5.16  1 0.19
4b 2R,5S 6.72 ± 0.15 1.06 ± 0.05 6.48 0.16
4c 2R,5R 7.04 ± 0.10 0.97 ± 0.04 6.61  ± 0.14
4d 2S,5S 5.02 ± 0.11 0.66 ± 0.05 4.98  -1 0.12
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Table 2. pEC50 values and affinity values of tetrahydrofuranylimidazoles for the human 
H4-receptor 
The pEC50 values were determined by the inhibition of the forskolin-stimulated (1  fuM) 
cAMP production, expressing the human H4- receptor. All  values shown are means  ± 
S.E.M. of at least four experiments. H4- receptor competition binding was performed 
using  [3H] histamine (10 nM).
Compounds Configuration
Functional activity Binding
 pEC5o Efficacy (a) pKi
Histamine 7.68 ± 0.05 1.00
(R)-a-Methylhistamine 6.26 ± 0.07 1.01  ±  0.01
 1a 2'S,5R 5.12 ± 0.05 1.02 ± 0.07 5.19  ± 0.07
 1b  2R,5S 5.26 ± 0.07 0.88 ± 0.06 5.60  ± 0.10
 lc [Imifuramine] 2R,5R 5.70 ± 0.05 0.70 ± 0.01 6.05  ± 0.04
 1d 2S,5S 4.51 ± 0.01 0.60 ± 0.04 4.89 0.06
2a 2S,5R 4.12 ± 0.08  0.71 ± 0.05 4.92  ± 0.16
2b 2R,5S 4.39 ± 0.04 0.74 ± 0.04 4.66  ± 0.12
2c 2R,5R 4.62 ± 0.08 0.76 ± 0.04 4.93 0.03
2d 2S,5S  4.07  ±  0.20 0.85 ± 0.11  <4
3a 2S,5R 5.12 ± 0.06 1.07 ± 0.01 5.09  ± 0.07
3b 2R,5S 6.65 ± 0.03 1.01 ± 0.01 6.65  ± 0.06
3c [OUP-16] 2R,5R 7.11 ± 0.05 0.99 ± 0.01 6.90 ± 0.17
3d 2S,5S 4.67 ± 0.03 1.06 ± 0.02 4.69-±0.12
4a 2S,5R 4.94 ± 0.03 0.82 ± 0.02  4.87±-0.07
4b 2R,5S 6.87 ± 0.05 0.91 ± 0.02 6.36 -± 0.11
4c 2R,5R 6.13 ± 0.10 0.46 ± 0.02 5.98 -± 0.12
4d 2S,5S 4.89  ± 0.08 0.49 ± 0.05 4.67 0.05
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 Figure 3. 
Relation of the functional  activity between the H3- and  H4- receptors. Data for 
tetrahydrofuranylimidazoles in Tables 1 and 2 are plotted as  H3-  EC50 values (ordinate, table 1) versus 
 H4- EC50 values (abscissa, table 2). Compound numbers correspond with those in Tables 1 and 2.  •, 
(2R,5S);  A,  (2S,5R)  ; (2R,5R);  ^ , (2S,5S)
 As shown in Figure 3,  lc,  1  d, 2c, 2d, 3b, and 3c exhibited receptor selectivity for 
either the hH3- or hH4- receptor. Amino compounds  lc,  1  d, 2c, and 2d showed 
selective  H3- agonistic activity, which was approximately 45-, 300-, 89- and 30-fold 
higher than for the H4- receptor, respectively. In contrast, the cyanoguanidine analogs 
3b and 3c exhibited full agonistic activities at the H4- receptor with 45- and 41-fold 
higher potency than at the H3- receptor, respectively. 
Conclusions 
 The substitution of an amino group of tetrahydrofuranylimidazoles with a 
cyanoguanidine moiety led to a decrease in the agonistic activity at the H3- receptor 
and an increase in the H4- receptor selectivity. The 3b and 3c  [OUP-16], having the 
2R-configuration,11 were highly selective compounds at the H4- receptor. On the other 
hand, 1 d, having the 2S,5S-configuration, behaved as the most selective H3- receptor 
agonist in our series. The present results suggest that the stereochemistry of the 
 tetrahydrofuranylimidazoles is useful for the investigation of selective ligands for  hH3-
and hH4- receptors and, that the 2R-configured isomers of cyanoguanidines exhibit a 
high agonistic activity for the H4- receptor. 
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Experimental Section 
  SK-N-MC cells expressing the  hH3-12 or hH4-  receptor' were maintained in Eagle's 
minimal essential medium (BioWhittaker, Verviers, Belgium) supplemented with 10% 
fetal calf serum (Integro, Zaandam, The Netherlands), 50  IU/mL penicillin, 
nonessential amino acids solution, 2 mM L-glutamine, 50  Rg/mL streptomycin, and 50 
 1.1g/mL sodium pyruvate  (lnvitrogen, Breda, The Netherlands) under the selection of 
600  pg/rinL  G418 disulfate (Calbiochem, Amsterdam, The Netherlands) at 37°C in a 
humidified atmosphere of 5 % CO2 in air by the method described by Wieland et al.13 
Cells were detached from the dishes with 0.05% trypsin-EDTA  (Invitrogen). 
  SK-N-MC cells stably expressing the hH3-12 or  hH4-receptors' were grown overnight 
in 96-well plates before the assay. To start the assay, the cells were incubated for 6 h 
with 1  .tM forskolin (Sigma-Aldrich, St. Louis, MO. USA) and respective 
tetrahydrofuranylimidazoles at 37°C. Thereafter, the medium was aspirated and cells 
were incubated overnight in a refrigerator with 100  tiL of assay buffer (100 mM 
 NaH2PO4, 100 mM  Na2HPO4, pH 8, 2 mM  MgSO4, 0.1 mM MnCl2, 0.5% Triton and 40 
mM  13-mercaptoethanol).13 Transcription of  3-galactosidase was determined by 4 mM 
 o-nitrophenyl-/3-D-galactopyranoside. Absorbance was quantified on a microplate 
reader at 420 nm. 
 The binding affinity of the hH3- and hH4- receptors was determined with 1.0 nM 
Na-methylhistamine (82 Ci/mmol, PerkinElmer Life Sciences, Zaventem, Belgium) 
and 10 nM  [3H] histamine (23.3 Ci/mmol, PerkinElmer Life Sciences), respectively. 
The Cell pellets were harvested, washed and homogenized in incubation buffer (50 
mM  Na2HPO4, pH 7.4). The cell homogenates (hH3-: 131  ± 11 fmol  / mg of protein, 
hH4-: 166 ± 26 fmol/mg of protein) were incubated for 1 h at 37°C with each 
radioligand in incubation buffer, pH 7.4, with or without competing ligands. Then, the 
membranes were filtered through the  GF/C filters pretreated with 0.3% 
polyethylenimine. The filter was washed three times with ice-cold washing buffer 
(hH3-: 25 mM Tris HCI, 145 mM NaCI, pH 7.4, hH4-: 50 mM Tris HCI, pH 7.4) and the 
radioactivity was determined by liquid scintillation counting. Nonspecific binding was 
defined with 1  !AM thioperamide as the competing ligand. 
 Protein concentrations were determined spectrophotometrically b  a Packard Argus 
400 Microplate Reader using the Bradford reagent,14 with bovine serum albumin as a 
standard. 
 The value of pKi and  pEC50 was obtained by fitting these data to a sigmoidal relation 
using GraphPad Prism (GraphPad Software, San Diego, CA). The intrinsic activities 
were calculated in comparison with the effects of histamine (100  RM). 
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Supporting Information 
Synthesis
 We previously reported the synthesis of the THFs and DHFs  (lb,  ld, 2b, and 2d) 
(Figure 1), which is characterized by use of a- or  /3-phenylselenenylnucleosides 6 or
8 (Scheme 1) as key intermediates, tarting from L-glutamic acid. Their enantiomers 
 la,  lc, 2a, and 2c (Figure 1) were also provided by the present methodology from 
D-glutamic acid. The four stereoisomers of the THFs  (1  b,  I  d, and their enantiomers) 
were first converted into the four cyanoguanidines 3b, 3d, 3a, and 3c (A in Figure 2), 
respectively, e.g., reaction of  1  b with dimethyl N-cyanodithioiminocarbonate in  Me0H 
at room temperature gave cyanomethyl-isothiourea 5 in a quantitative yield (Scheme 1, 
eq. 1). Subsequent treatment of 5 in 40%  MeNH2 in  Me0H produced the 
cyanoguanidine 3b in a 92% yield as a single isomer, although the geometry for the 
cyanoguanidine moiety remains undetermined. The four isomers 4b, 4d, 4a, and 4c 
(B in Figure 2) of  4(5)-(5-benzyloxy-methyltetrahydrofurany-2-y1)-1H-imidazoles 
were also provided by alkaline hydrolysis of the synthetic intermediates 7, 9 described 
in Scheme 1, and their enantiomers [e.g., 7 to 4b (91 %) in Scheme 1, eq. 2].
Reagents: a) (MeS)2C=NCN; b)  MeNH2; 
      c) ref. 10; d)  1N NaOH
Scheme 1 
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Experimental Section 
  Chemistry. The ORD spectra were recorded at 25°C.  1H and  13C NMR spectra 
were taken with tetramethylsilane. Reactions with air- and moisture-sensitive 
compounds were carried out under an argon atmosphere. Unless otherwise noted, 
all extracts were dried over  Na2SO4, and the solvent was removed in a rotary 
evaporator under reduced pressure. Chromatography was performed on silica gel. 
 THE was distilled from sodium-benzophenone. 
 (+)-2-Cyano-l-methy1-3-{(2S,5R)-541H-imidazol-4(5)-yl]tetrahydrofuran-2-yll 
methylguanidine  [3b]. A solution of  lb (99 mg, 0.59 mmol) and dimethyl 
N-cyanodithioiminocarbonate (192 mg, 1.18 mmol) in  Me0H (10 mL) was stirred for 
1.5 h at room temperature. After evaporation of the solvent, the residue was 
chromatographed [Chromatorex NH-DM 1210,  EtOAc] to give 5 (157 mg, quant) 
 [1H-NMR  (CD3OD):  81.72-1.93 (m,  1H), 1.99-2.35 (m, 3H), 2.60 (s, 3H), 3.49 (dd,  1H, 
 J  13.5,  6.5  Hz),  3.63  (dd,  1H,  J  13.5,  5.0  Hz),  4.25  (ddd,  1H,  J  15.0,  6.5,  5.0  Hz)]. 
The cyanomethylisothiourea 5 was subsequently dissolved in 40%  MeNH2 in  Me0H 
(10 mL). The resulting mixture was stirred for 3 h at room temperature. The solvent 
was evaporated to give a residual oil, which was chromatographed [Chromatrex 
NH-DM 1210,  Me0H-Et0Ac  (1  : 9)] to give 3b (135 mg, 92%) as a white amorphous 
product. ORD  (c 2.40,  EtOH) [a] (nm): +35.1 (589), +42.6 (550), +57.6 (500), +70.2 
(450), +97.7 (400), +142.8 (350), +238.0 (300).  IR (neat): 2170 (CN)  cm-1.  1H-NMR 
 (CD3OD):  8 1.78-2.28 (m, 4H), 2.73 (s, 3H), 3.29-3.43 (overlapped with CH3OH in 
 CD3OD), 4.17 (m,  1H), 4.97 (overlapped with  H2O in  CD3OD), 7.06 (s,  1H), 7.68 (s, 
1H). 13C-NMR  (CD3OD):  6 28.9, 29.9, 33.0, 47.6, 77.1, 80.2, 117.0, 120.3, 137.2, 
162.7.  EIMS m/z 248 (M+). HRMS m/z 248.1393 (calcd for  C11H16N60: 248.1385). 
 (+)-2-Cyano-1-methyl-3-{(2S,5S)-241H-imidazol-4(5)-ylltetrahydrofuran-2-yll 
methylguanidine [3d]. A solution of  ld (33 mg, 0.20 mmol) and dimethyl 
N-cyanodithioiminocarbonate (96 mg, 0.59 mmol) was stirred at room temperature for 
18 h, and 40%  MeNH2 in  Me0H (1.2 mL) was then added to the solution. After the 
resulting mixture was stirred for 3 h at room temperature, a small amount of silica gel 
(NH-DM 1210) was added to the reaction mixture. The solvent was evaporated to 
give a coated silica gel, which was subsequently placed in a column. 
Chromatography with  Me0H-Et0Ac  (1  : 19) as the eluent gave 3d (44 mg, 89%) as a 
white amorphous product. ORD (c 2.25,  EtOH) [a] (nm): +19.6 (589), +21.4 (550), 
+31.2 (500), +41.0 (450), +53.5 (400), +78.4 (350), +128.3 (300). IR (neat): 2170 (CN) 
 cm-1.  1H-NMR  (CD3OD):  61.72-1.88 (m,  1H), 2.06-2.36 (m, 3H), 2.58 (s,  1H), 2.79 
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(s, 2H), 3.23-3.50 (overlapped with CH3OH in  CD3OD), 4.31 (m,  1H), 5.05 (overlapped 
with  H2O in  CD3OD), 7.02 (s,  1H), 7.64 (s,  1H). 13C-NMR  (CD3OD):  829.0, 30.6, 33.4, 
47.2, 76.2, 79.6, 118.0, 120.2, 137.2, 162.6.  EIMS m/z 248 (M+). HRMS m/z 
248.1383 (calcd for  C11H16N60: 248.1385). 
 (+)-(2R,5S)-4(5)-(5-Benzyloxymethyltetrahydrofurany-2-y1)-1H-imidazole  [4b].
A solution of 7 (219 mg, 0.66 mmol) in  Me0H (10 mL) was stirred with  1N NaOH (6.6 
mL) at room temperature for 1 h. The resulting mixture was extracted with  EtOAc 
3) by the salting-out echnique. The extract was dried and evaporated. The residual 
oil was chromatographed  [Me0H-Et0Ac  (1% to 8%)] to give 4b (171 mg,  91%) as an 
oil. ORD  (c 2.10,  Me0H)  [a] (nm): +8.3 (589), +9.3 (550), +11.4 (500), +13.3 (450), 
+19.0 (400), +24.8 (350). IR (neat): 1160-1030 (C-O-C)  cm-1. 1H-NMR (CDCI3):  8
1.92-2.40 (m, 4H), 3.61 (dd,  1H,  J  =  10.4,  5.6  Hz), 3.80 (dd,  1H,  J  = 10.4, 5.6 Hz), 4.24 
(m,  1H), 4.58 (bs, 2H), 5.13 (m,  1H), 6.83 (s,  1H), 7.10 (s,  1H), 7.38 (m, 6H), 8.2-8.4 
(bs,  1H, NH).  EIMS m/z 258 (M+). HRMS m/z 258.1371 (calcd for  C15H181\1202: 
 258.1367). 
 (-)-(2S,5S)-4(5)-(5-Benzyloxymethyltetrahydrofurany-2-yI)-1H-imidazole [4d1. A 
mixture of 9 (337 mg, 1.02 mmol) and  1N NaOH (10 mL) in  Me0H (7 mL) was stirred 
for 1 h at room temperature to give 4d (253 mg, 96%) as an oil by the same procedure 
for the preparation of 4b. ORD (c 5.05,  EtOH) [a] (nm): -25.8 (589), -31.7 (550), 
-39.6 (500), -53.5 (450), -75.2 (400), -116.8 (350). IR (neat): 1040-1150 (C-O-C) 
 cm-1.  1H-NMR (CDCI3):  8 1.72-2.35 (m, 4H), 3.55 (d, 2H, J = 6.5 Hz), 4.35 (m,  1H), 
4.57 (s, 2H), 5.07 (t,  1H,  J  = 6.5 Hz), 6.85 (s,  1H), 7.33 (m, 5H), 7.49 (s,  1H), 8.0 (bs, 
 1H, NH).  EIMS m/z 258 (M+). HRMS m/z 258.1381 (calcd for  C15H181\1202: 
258.1367). 
 The configuration counterparts were synthesized by the present method. Their 
ORD values are described below. 
 3a  : ORD (c 1.32,  EtOH)[a] (nm):  -41.1  (589),  -50.2 (550), -63.9 (500), -82.1 (450), 
-111.8 (400), -159.7 (350), -264.6 (300). 
 3c  : ORD  (c 1.30,  EtOH) [a] (nm): -14.7 (589), -15.4 (550), -18.5 (500), -20.1 (450), 
-24.7 (400), -29.3 (350). 
 4a  : ORD (c 3.30,  EtOH) [a] (nm): -4.2 (589), -6.0 (550), -7.2 (500), -10.6 (450), 
-13.3 (400). 
 4c : ORD (c 3.20,  EtOH) [a] (nm): +24.0 (589), +30.5 (550), +37.0 (500), +50.2 
(450), +72.8 (400). 
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ABSTRACT 
Agonist-independent activity of G-protein-coupled receptor, also referred to as 
constitutive activity, is a well-documented phenomenon and has been reported 
recently for both the histamine H1- and H2- receptors. Using SK-N-MC cell lines stably 
expressing the human and rat H3- receptors at physiological receptor densities 
(500-600 fmol/mg of protein), we  .show that both the rat and human H3- receptors 
show a high degree of constitutive activity. The forskolin-mediated cAMP production in 
SK-N-MC cells is inhibited strongly upon expression of the Gi -coupled H3- receptor. 
The cAMP production can be further inhibited upon agonist stimulation of the  H3-
receptor and can be enhanced by a variety of H3- antagonists acting as inverse 
agonists at the H3- receptor. Thioperamide, clobenpropit, and iodophenpropit raise the 
 cAMP levels in SK-N-MC cells with potencies that match their receptor binding 
affinities. Surprisingly,  impentamine and burimamide act as effective H3- agonists. 
Modification of the amine group of impentamine dramatically affected the 
pharmacological activity of the ligand. Receptor affinity was reduced slightly for most 
impentamine analogs, but the functional activity of the ligands varied from agonist to 
neutral antagonist and inverse agonist, indicating that subtle changes in the chemical 
structures of impentamine analogs have major impact on the (de)activation steps of 
the H3- receptor. In conclusion, upon stable expression of the rat and human  H3-
receptor in SK-N-MC cells constitutive receptor activity is detected. In this 
experimental system, H3- receptors ligands, previously identified as H3 antagonists, 
cover the whole spectrum of pharmacological activities, ranging from full inverse 
agonists to agonists. 
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  The histamine H3- receptor was discovered in 1983 by Arrang and coworkers as a 
presynaptic autoreceptor regulating the release of histamine from histaminergic 
neurons (Arrang et al., 1983). Since then, the H3- receptor has been shown to act as 
heteroreceptor as well, inhibiting the release of important neurotransmitters, e.g., 
 acetylcholine, glutamate, nor-adrenaline, and serotonin (Leurs et al., 1998). With the 
avail-ability of a variety of selective and potent H3- agonists and antagonists (Leurs et 
al., 1995; Stark et al., 1996), it has become clear that the H3- receptor is involved in the 
regulation of several important physiological processes. Consequently, the  H3-
receptor is regarded as an interesting target for the modulation of a variety of functions 
such as cognitive processes, epilepsy, food intake, and sleep-wakefulness (Leurs et 
al., 1998). 
 Despite the interest in H3- receptor ligands for therapeutic application, the actual 
therapeutic development has for a long time been hampered by the lack of information 
on the molecular target. Whereas the cloning of the H1- and H2- receptor genes was 
reported in the early 90s (Gantz et  al.,- 1991; Yamashita et al., 1991), it was 1999 
before the gene of the human H3 receptor was cloned finally by Lovenberg et al. 
(1999) after the identification of a partial sequence of an orphan G-protein-coupled 
receptor (GPCR) in the  Incyte expressed sequence tags database. The H3- receptor 
was shown finally to be a GPCR with only limited homology (<30%) with the H1- and 
H2- receptor genes (Lovenberg et al., 1999). 
 Classical models of GPCRs require agonist occupation of receptors to activate 
signal transduction pathways. Yet, it is now well-documented that GPCRs can be 
spontaneously active, and this agonist-independent receptor activity is often referred 
to as constitutive receptor activity (Costa et al., 1992; Lefkowitz et al., 1993; Milligan et 
al., 1995). Inverse agonists reduce the constitutive GPCR activity, whereas neutral 
antagonists do not affect the basal GPCR activity but prevent the action of both 
agonists and inverse agonists. Constitutive activity has been shown recently for both 
the histamine H1- and H2- receptors  (Smit et al., 1996; Bakker et al., 2000), and we 
reported that the therapeutically important H1- and H2- antagonists, in fact, act as 
inverse agonists. In the present study, we describe that the human and rat histamine 
H3 receptors tably expressed in SK-N-MC cells (Lovenberg et al., 1999, 2000) show a 
high level of constitutive activity, resulting in the identification of several standard  H3-
antagonists (thioperamide and clobenpropit) as in-verse agonists in this cell system. 
Moreover, burimamide and impentamine, previously identified as H3- antagonists 
(Arrang  et al., 1983; Vollinga et al., 1995a, 1995b), behave as H3- agonists at the 
recombinant H3- receptors. The agonistic effects of impentamine could also be 
demonstrated on the hypothalamic histamine release in the rat brain using in vivo 
microdialysis. Moreover, in a series of impentamine analogs we were able to 
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manipulate the intrinsic activity. VUF4904, an impentamine analog with an isopropyl 
group at the amino group of the side chain, bound with a relatively high affinity (12 nM) 
and acted as a neutral antagonist in the transfected SK-N-MC cells. These data 
indicate that ligands, previously identified as H3- antagonists, can cover the whole 
spectrum of pharmacological ctivities, ranging from full inverse agonism to agonism, 
at the recombinant  H3- receptors heterologously expressed in SK-N-MC cells. 
Experimental Procedures 
Materials 
 (R)-a-Methylhistamine dihydrobromide was obtained from Sigma Research 
Biochemicals Inc. (Zwijndrecht, The Nether-lands). Burimamide was a kind gift of 
GlaxoSmithKline (Welwyn Garden City, Hertfordshire,  UK). All other H3- ligands were 
taken from laboratory stock or (re-)synthesized at the Vrije Universiteit Amsterdam 
(details will be published elsewhere). Forskolin,  3-isobu-tyl-1-methylxanthine, cyclic 
3',5'-adenosine monophosphate (cAMP), pertussis toxin, and bovine serum albumin 
were obtained from Sigma. Dulbeccos's modified Eagle's medium, trypsin-EDTA, 
peni-cillin, nonessential amino acids, L-glutamine, streptomycin, and sodium-pyruvate 
were from  Invitrogen (Breda, The Netherlands). Eagle's minimal essential medium 
was from BioWhittaker (Verviers, Belgium), and fetal calf serum was from Integro 
(Zaandam, The Netherlands).  CultUre dishes and 24-well plates were from Costar 
(Haarlemermeer, The Netherlands). G418 was obtained from Calbiochem 
(Amsterdam, The Netherlands).  [3H]cyclic 3',5'-adenosine monophosphate  ([3H]cAMP), 
40 Ci/mmol, was from Amersham (s'Hertogenbosch, The Netherlands); 
 [31-1]Ar-methylhistamine, 85 Ci/mmol, was from PerkinElmer Life Sciences (Zaventem, 
Belgium). 
Cell Culture 
 SK-N-MC cells, a human neuroblastoma cell line stably expressing the human 
histamine H3 receptor (the 445-amino acid isoform) or the rat histamine H3A- receptor 
(Lovenberg et al., 1999, 2000), were grown in 10-cm 2 dishes at 37°C in a humidified 
atmosphere with 5%  CO2 in Eagle's minimal essential medium, supplemented with 
10% v/v fetal calf serum, 50  IU/m1 penicillin, nonessential amino acids, 2 
mML-glutamine, 50  Ng/ml streptomycin, and 50  pg/ml sodium-pyruvate in presence of 
600  pg/ml  G418. Cells were detached from the dishes with 0.05% trypsin-EDTA. 
 fHpV2-Methylhistamine Binding 
 Confluent 10-cm dishes of SK-N-MC cells stably expressing the rat or human 
histamine H3- receptor were harvested using a cell scraper and centrifuged (3  min, 
500g), and the pellets were stored at -20°C until the day of the experiment. Before use 
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the pellets were dissolved in distilled water and homogenized for 2 s bysonication (40 
Watt, Labsonic 1510). The cell homogenates (30-100  pg) were incubated for 40  min 
at 25°C with 1 nM  [3H]W-methylhistamine (85.0 Ci/mmol) in 50 mM sodium phosphate 
buffer, pH 7.4, with or without competing ligands. The  reaction  was terminated by rapid 
dilution with 3 ml of ice-cold buffer, pH 7.4, and filtration over 0.3% 
polyethylenimine-pretreated What-mann GF/C filters with two subsequent washes with 
3 ml of buffer. Retained radioactivity was determined by liquid scintillation counting. 
Nonspecific binding was defined with 100 pM thioperamide as competing ligand. 
 Protein concentrations were determined spectrophotometrically (Packard Argus 400 
Microplate Reader) using the Bradford reagent (Bradford, 1976), with bovine serum 
albumin as a standard. 
Measurement of cAMP 
 SK-N-MC cellsstably expressing either the rat or human H3- receptor were grown 
overnight in 24-well plates (4.5 x 106 cells/plate), washed once with Dulbeccos's 
modified Eagle's medium/HEPES (25 mM, pH 7.4 at 37°C), and preincubated in the 
same medium for 30  min at 37°C. Thereafter the cells were incubated for exactly 10 
 min with fresh medium supplemented with 0.3 mM  3-isobuty1-1-methylxanthine, 10 pM 
forskolin, and the re-spective ligands. To stop the incubation the medium was 
discarded, 200  pl of ice-cold HCI (0.1 M) was added, and the samples were 
homogenized for 2 s (40 Watt, Labsonic 1510) and frozen at -20°C. 
 The intracellular cAMP concentration was determined in a competitive binding 
assay in which the formed cAMP competes with  [3H]cAMP for binding to protein kinase 
A (Nordstedt and Fredholm, 1990). To this end, plates were thawed quickly and 
neutralized with 1 M  NaOH. To 25 to 200  pl cell homogenate, 50  pl of  [3H]cAMP, 200 
 pl of protein kinase A suspension, and cAMP assay buffer (Nordstedt and Fredholm, 
1990) were added to reach a total volume of 450  pl. After 2.5 h at 4°C, the reaction 
was terminated by rapid dilution with 3 ml of ice-cold 50 mM Tris-HCI, pH 7.4 at 4°C 
and filtration over Whatmann GF/B filters with two subsequent  3-ml washes. Retained 
radioactivity was  determined by liquid scintillation counting. From a cAMP standard 
curve (0, 32, 16, 8, 4, 2, 1, 0.5, and 0.25  pmol/100  pl) the amount of cAMP in each 
sample was calculated using the non-linear egression-fitting program AssayZap. 
In Vivo Microdialysis 
 Male Wistar rats weighing about 250 g were anesthetized with urethane (1.2 g/kg, 
i.p.) and placed in  a  stereotaxic apparatus. A dialysis probe  (CMA/10; membrane 
length, 2 mm;  CMA/Microdialysis AB, Stockholm, Sweden) was inserted into the 
anterior hypothalamic area with coordinates of AP, 1.5; L, 0.5; and V, 9.2 mm relative 
to the bregma, according to the atlas of Paxinos and Watson (1986). The anterior 
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hypothalamic area was perfused with artificial cerebrospinal f uid containing 140 mM 
NaCI, 3 mM KCI, 2.5 mM  CaCl2, 1 mM  MgCl2, and 5 mM glucose, pH 7.4, through a 
dialysis probe at 1  pl/min using a microinfusion pump  (CMA100, CMA/Microdialysis 
AB). Two hours after the insertion of a probe, samples were collected every 20  min 
with a minifraction collector  (CMA140,  CMA/Microdialysis AB) and frozen immediately 
at -40°C until analysis.  Impentamine and clobenpropit were added to cerebrospinal 
fluid at the concentration of 10  pM and adminis-tered through the dialysis membrane. 
After the experiment, the brains were removed for histological verification of sites of 
infusion. 
 The concentration of histamine in the perfusate was assayed by HPLC (Yamatodani 
et al., 1985; Mochizuki et al., 1991) The recovery of histamine through the 
microdialysis membrane is about 40% (Mochizuki et al., 1991). 
 In each microdialysis experiment, he average of the first three fractions was defined 
as basal release, and the subsequent fractions were expressed as a percentage of 
this. The statistical differences between groups were analyzed initially using one-way 
analysis or variance for repeated measurements. Ifsignificant effects versus the basal 
release were found, data were further analyzed by post hoc Newman-Keuls test. 
Data Analysis 
 For the binding studies  p/C50 (negative logarithm of the ligand concentration that 
displaces the radioligand half-maximally) and pKd values  (negative logarithm of the 
equilibrium dissociation constant of the radioligand, i.e., the concentration, that 
occupies 50% of the available receptors at equilibrium) were calculated using 
nonlinear egression analysis using GraphPad Prism (Graph-Pad Software, San Diego, 
CA) and converted to pKi values (negative logarithm of the equilibrium dissociation 
constant for binding of the unlabeled drug) using the Cheng-Prusoff equation (Cheng 
and Prusoff, 1973). From the cAMP data pEC50 (negative logarithm of the ligand 
concentration, that activates the receptor half-maximally) and  p/C50 values (negative 
logarithm of the ligand concentration, that inhibits the receptor half-maximally) were 
obtained by fitting these data to a sigmoidal relationship using GraphPad Prism. The 
intrinsic activities were calculated in comparison with the effects of the full agonist 
 (R)-a-methylhistamine (1  pM) or the full inverse agonist iodophenpropit (10  pM). 
 All data are presented as mean ± S.E.M.; statistical comparisons wereperformed 
using the Student's  t  test. 
Results 
 The generation of the SK-N-MC cells stably expressing either the rat or human 
histamine H3- receptor was described previously (Lovenberg et al., 1999, 2000). In the 
present study, we used SK-N-MC cell lines, expressing 516  ±  23 fmol/mg of protein (n 
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= 3) of the human histamine H3- receptor or 627 ± 87 fmol/mg of protein (n = 3) of the 
rat histamine H3- receptor, as assessed by  [3H]!f-methylhistamine binding. 
 As described previously, the H3- agonists (R)-a-methylhistamine (pEC50 = 9.26 ± 
0.08) and imetit  (pEC50  = 9.28 ± 0.04) potently inhibited the 10 pM forskolin-stimulated 
production of cAMP in human H3- receptor expressing cells (Fig. 1A; Table 1). In 
contrast,  (R)-a-methylhistamine had no effect in the parental SK-N-MC cell line (Fig. 
 1A). As expected for a Gi-coupled receptor, the 1  iuM (R)-a-methylhistamine effects at 
the human H3- receptor (reduction to 11 ± 3% of the forskolin-induced cAMP levels) 
were abolished completely by an overnight pretreatment with 100 ng/ml pertussis toxin 
(99 ± 10% of forskolin-induced cAMP level,  not shown). 
 Interestingly, we noticed an important difference between the forskolin-induced 
cAMP levels of the parental SK-N-MC cell line and the H3- receptor expressing cells 
(Fig.  1B). As this could be an indication of constitutive H3- receptor activation, we 
tested a variety of previously identified H3- antagonists on the SK-N-MC cell line 
expressing the human H3- receptor. Standard H3- antagonists as thioperamide, 
clobenpropit, and iodophenpropit concentration-dependently increased the forskolin-
induced cAMP levels in the transfected SK-N-MC cells (Fig.  1B; Table 1), whereas 
clobenpropit had no effect on the forskolin response in the parental cell line (Fig.  1B). 
In our experiments, iodophenpropit and clobenpropit acted as full inverse agonists (a 
 = -1.0 -0.9), whereas thioperamide acted as a partial inverse agonist  (Table 1). The 
obtained pEC50 values for the various inverse agonists correspond well with the 
respective affinities, as obtained in  [3FI]AP-methylhistamine competition experiments 
(Table 1). 
 In search of neutral antagonists, we tested a variety of other H3- antagonists. 
Surprisingly, the presumed H3- antagonists burimamide, impentamine, and the imetit 
homolog VUF 8328 (Van der Goot et al., 1992) all acted as potent H3- agonists at the 
human H3- receptor with intrinsic activities between 0.8 and 0.9 (Fig. 2; Table 1). 
Comparing the pKi values of various agonists with their  pEC50 values revealed that in 
general the potencies of the agonists nicely parallel their affinities (Table 1). Only for 
the full agonists (R)-a-methylhistamine and perhaps imetit may some sort of receptor 
reserve be noticed (Table 1). 
 Based on the  'identification of  agonism  of impentamine, we studied several 
impentamine analogs to identify a neutral H3- receptor antagonist. In this series of  H3- 
ligands, the amine function of impentamine was substituted or incorporated in a 
piperidine ring. Modification of the amine group results in a series of compounds with a 
wide spectrum of pharmacological ctivity, including the neutral antagonist VUF4904 
(Fig. 3; Table 2). 
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Fig. 1. Modulation of 10 pM forskolin induced cAMP production in SK-N-MC cells, expressing the 
human H3- receptor. A, effects of the H3- agonist (R)-a-methylhistamine on the forskolin response in 
SK-N-MC cells or SK-N-MC cells expressing the human H3- receptor. B, effects of the H3- inverse 
agonists clobenpropit and  iodophenpropit  on the forskolin response in SK-N-MC cells expressing the 
human H3- receptor. For comparison, the effects of clobenpropit on nontransfected SK-N-MC cells is 
shown. Cells were incubated for 10  min with the indicated ligands. After termination of the incubation 
the cAMP levels were determined by a competitive binding assay.
 TABLE 1 Affinities and functional activities of several H3- receptor ligands at the human H3- receptor 
 H3- receptor affinity  (WO) was determined by  [31-1]-Na-methylhistamine bi ding to membranes of 
 SK-N-MC cells expressing the human H3- receptor. For agonists the pEC50 values were determined by 
 the inhibition of the forskolin-stimulated (10  pM) cAMP production, whereas the inverse agonistic 
 activity was determined by the increase of the forskolin response in SK-N-MC cells, expressing the 
 human H3- receptor. All data shown are the mean ± S.E. of at least three experiments. * indicates a 
 significant difference compared with  (R)-a-methylhistamine.  ** indicates a significant difference 
 compared with iodophenpropit.
Ligand  PKi  pEC50 a
 (A)-a-Methylhistamine 8.36 ± 0.07 9.26 ± 0.08 1.0  ±  0.05
 'meth 8.79 ± 0.08 9.28 ± 0.04 1.0  ±  0.02
 VU  F8328 8.48  ± 0.01 8.86  ± 0.06 0.9 ± 0.03
Impentamine 8.29 ± 0.14 8.63 ± 0.23 0.9 ± 0.08
Burimamide 7.11  ±  0.1 6.67 ± 0.14 0.8 ± 0.09*
lodophenpropit 8.15 ± 0.05 7.60 ± 0.08 -1.0 ± 0.07
Thioperamide 7.18 ± 0.03 6.73  ± 0.20 -0 .7 ±  0.1**
Clobenpropit 8.42 ± 0.02 8.44 ± 0.15 -0 .9  ± 0.1
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  Constitutive activity is not restricted to the human H3 receptor. Whereas the rat and 
human H3- receptor were ex-pressed at similar levels (627  fmol/mg of protein versus 
516 fmol/mg of protein), the forskolin-induced cAMP levels were always lower in the 
SK-N-MC cells expressing the human H3- receptor (Fig. 4). These data indicate that in 
our experimental model the level of constitutive activity of the human H3- receptor is 
more pronounced than that of the rat H3- receptor. At the recombinant rat receptor, the 
H3- ligands burimamide and impentamine also behave as H3- agonists. In contrast o 
the human H3- receptor, both ligands behave as full agonists at the rat H3- receptor 
(Table 3). The constitutive activity, displayed by the rat H3- receptor, can also be 
inhibited by compounds such as clobenpropit (Fig. 4; Table 3). Especially for the 
inverse agonists thioperamide and iodophenpropit, we confirmed the reported species 
differences (Lovenberg et al., 1999, 2000) with respect to their potencies in both 
receptor binding and functional assays (Table 3). 
 To investigate the predictive value of the data obtained with the recombinant 
receptors, impentamine and clobenpropit were tested in vivo. Previously, we showed 
by microdialysis the H3- receptor-mediated effect on in  vivo histamine release in the rat 
hypothalamus (Jansen et al., 1998). Using the same experimental set-up, we first 
evaluated the effects of impentamine. The mean values ± S.E.M. of the basal 
histamine release in the experiments in Fig. 5 were 0.078 ± 0.008 (n = 4)  pmol/20  min. 
This value remained constant throughout the experimental period of 5 h under 
anesthesia (data not shown). After infusion of impentamine the histamine levels in the 
hypothalamus rapidly decreased to approximately 40% of the basal levels. 
Concomitant infusion of clobenpropit reversed the effect of impentamine and even 
caused an increase (± 40%) in the histamine release above basal levels (Fig. 5). 
Discussion 
 The recent cloning of the rat and human H3- receptor cDNAs by Lovenberg et al. 
(1999, 2000) has had a great impact in the field of histamine research. The new 
information has been instrumental in identifying H3- receptor isoforms (Drutel et al., 
2001) and the H4- receptor (Nakamura et al., 2000; Oda et al., 2000; Liu et al., 2001; 
Morse et al., 2001; Nguyen et al., 2001; Zhu et al., 2001) and has also been essential 
in deriving important information about the signaling properties of the H3- receptor. 
Whereas for many years the actual signaling pathways for the H3- receptor had been 
un-known, the use of cell lines expressing the H3- receptor has led to the identification 
of at least three signal transduction pathways for the H3- receptor: a Gi -mediated 
inhibition of adenylate cyclase (Lovenberg et al., 1999, 2000; Drutel et al., 2001), the 
activation of the MAP kinase pathway (Drutel et al., 2001), and the stimulation of 
 Na+/Wexchange (Silver et al., 2001). 
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 Using SK-N-MC cell lines, stably expressing either the human and rat H3- receptors 
at physiological receptor densities (500-600  fmol/mg of protein)  (Yanai et al., 1994; 
Brown et al., 1996), we now show that both the rat and human  I-13- receptor display a 
high degree of constitutive activity. The forskolin-mediated cAMP production in 
SK-N-MC cells is inhibited strongly upon expression of the Gi -coupled H3- receptor. 
The cAMP production can be further inhibited upon agonist stimulation of the  H3-
receptor and can be enhanced by a variety of H3- antagonists acting as inverse 
agonists at the H3- receptor. Thioperamide, clobenpropit, and iodophenpropit raise the 
cAMP levels in SK-N-MC cells expressing either the human or rat H3- receptor with 
potencies that match their receptor binding affinities. As reported previously 
(Lovenberg et al., 1999, 2000), an important species difference is noticed for 
thioperamide in both the binding and cAMP assay.
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Fig. 2. Agonistic activity of (R)-a-methylhistamine (RAMH) and burimamide in SK-N-MC cells 
expressing the human H3- receptor. SK-N-MC cells expressing the human H3- receptor were stimulated 
with 10 pM forskolin in the presence of increasing concentrations of the H3- ligands for 10  min. After 
termination of the incubation the cAMP levels were deter-mined by a competitive binding assay.
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Fig. 3. Modulation of 10  pM forskolin induced cAMP production in SK-N-MC cells expressing the human 
H3- receptor by a variety of impentamine analogs. SK-N-MC cells expressing the human H3- receptor 
were stimulated with 10 pM forskolin in the presence of increasing concentrations of the H3- ligands for 
10  min. For comparison the effects of clobenpropit and (R)-a-methylhistamine are shown as well. After 
termination of the incubation the cAMP levels were determined by a competitive binding assay.
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Fig. 4. Modulation of 10 pM forskolin induced cAMP production in SK-N-MC cells expressing the human 
or rat H3- receptor, by the inverse agonists clobenpropit or  iodophenpropit. SK-N-MC cells were 
stimulated with 10  pM forskolin in the presence of increasing concentrations of H3- ligand for 10  min. 
After termination of the incubation, the cAMP levels were determined by a competitive binding assay.
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  Burimamide was one of the key compounds used by Arrang et al. (1983) to 
demonstrate pharmacologically the existence of the H3- receptor in rat cerebral cortex 
slices. Remarkably, at recombinant H3- receptors, the presumed H3- antagonist 
burimamide acts as a H3- agonist. Whereas at the human H3- receptor burimamide 
acts as a partial agonist  ( a = 0.8), full agonism is observed at the rat receptor. It is 
interesting to note that via the use of heterologous expression systems, burimamide is 
reclassified for the second time. Previously, we showed that at the human H2- receptor 
burimamide acts as a weak partial agonist (Alewijnse et al., 1998). Because 
burimamide was developed originally as an H2- antagonist using histamine as a 
starting point (Black et  al., 1972), the discovery of residual agonistic activity at 
histamine H2- and H3- receptors is perhaps not too surprising. 
 The use of transfected cell lines also suggests a reclassification for impentamine, 
the histamine homolog previously suggested to differentiate between H3- receptors in 
the guinea pig intestine and rat or guinea pig brain (Leurs et  al., 1996; Harper et al., 
1999).  lmpentamine is a potent H3- antagonist in the guinea pig intestine (pA2 = 8.4), 
but a partial agonist in the rat brain (pD2 = 8.2, a = 0.6) (Leurs et al., 1996). Moreover, 
radioligand binding studies at the H3- receptor in the guinea pig brain and intestine 
indicated that impentamine can discriminate between the receptors in the two 
preparations (Harper et al., 1999). At both the recombinant rat and human  H3-
receptors, impentamine behaves as an effective agonist. Moreover, in vivo 
microdialysis shows that impentamine also acts as an H3- agonist  In the rat 
hypothalamus, inhibiting the basal release of histamine. Previously we showed that 
potent H3- agonists, like immepip (Jansen et  al., 1998), inhibit the hypothalamic 
histamine release to approximately the same extent as observed in this study for 
impentamine. 
TABLE 2 Affinities and functional activities of several impentamine a alogs at the human H3- receptor 
H3- receptor affinity  (plc) was determined by  [3F1]-AF-methylhistamine bind gto membranes of 
SK-N-MC cells expressing the human H3- receptor. For agonists he pEC50 values were determined by 
the inhibition ofthe forskolin-stimulated (10  pM) cAMP production, whereas the inverse agonistic 
activity was determined bythe increase of the forskolin response inSK-N-MC cells, expressing the 
human H3- receptor. Alldata shown are the mean ± S.E. of at least hree xperiments. 
 Ligand  PK/  pECso a 
 Impentamine 8.29 ± 0.14 8.63 ± 0.23 0.9 ± 0.08 
   VUF5300 8.05 ± 0.09 8.67 ± 0.18 1.0 ± 0.02 
   VUF5207 7.81  ±0.18  7.89  ±  0.1  0.7  ±  0.05a 
  VUF4904 7.89 ± 0.05  -0.1 ±  0.1a 
   VUF4903 7.97 ± 0.03 8.10  ±  0.17 -0.6 ± 0.1b 
   VUF5202 8.63 ± 0.04 8.66  ± 0.11 -0.9 ± 0.1 
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TABLE 3 
Affinities and functional activities of several H3- receptor ligands at the rat and human H3- receptor 
H3- receptor affinity (pKi) was determined by  [31-1]-Na-methylhistamine bi ding to membranes of 
SK-N-MC cells expressing the human or rat H3- receptor. For agonists the  pEC50 values were 
determined by the inhibition of the forskolin-stimulated (10 pM) cAMP production, whereas the inverse 
agonistic activity was determined by the increase of the forskolin response in SK-N-MC cells, 
expressing the H3- receptor. All data shown are the mean ± S .E. of at least three experiments.
Ligand
Human H3 Human H4
pKi  pECso a pKi  pECso a
 (R)-a-Methylhistamine8.36 ± 0.07 9.26 ± 0.08 1.0 ± 0.05 8.04 ± 0.05 9.22 ± 0.16  1.0  ±  0.10
Impentamine 8.29 ± 0.14 8.63 ± 0.23 0.9 ± 0.08 8.30 ± 0.3 9.03 ± 0.13 1.1  ±  0.1
Burimamide 7.11  ±  0.1 6.67 ± 0.14 0.8 ± 0.09a 7.32 ± 0.09  7.16 ± 0.01 1.1  ±  0.02
lodophenpropit 8.15 ± 0.05 7.6 ± 0.08 1.0 ± 0.07 8.83 ± 0.07 8.03 ± 0.19 1.0 ± 0.05
Clobenpropit 8.42 ± 0.02 8.44 ± 0.15 0.9 ± 0.1 9.06 ± 0.08 8.54 ± 0.12 1.0 ± 0.1
Thioperamide 7.18 ± 0.03 6.73 ± 0.2 0.7 ±  0.1b 8.19 ± 0.02 8.09 ± 0.4 1.0 ± 0.07
a Indicates a significant difference compared with (R)-a-methylhistamine. 
b Indicates a significant difference compared with iodophenpropit.
 Although constitutive GPCR activity is now a widely accepted pharmacological 
concept, effects due to the presence of the natural agonist cannot be ignored 
completely. The identification of neutral antagonists has resolved this issue for the 
histamine H2- receptor and led to the recognition that the therapeutically important  H2-
antagonists are in fact inverse agonists (Smit et al., 1996). To identify a neutral  H3- 
antag-onist we tested a variety of impentamine analogs at the human  I-13- receptor. 
The amine function of impentamine probably interacts with the aspartate residue Asp 
114 in transmembrane domain 3, which is highly conserved in the family of biogenic 
amines (De Esch et al., 2000). We hypothesized that modification of the amine 
function potentially could affect the agonistic properties of impentamine. Indeed, 
modification of the amine group dramatically affected the pharmacological ctivity of 
the ligand. Receptor affinity was reduced slightly for most analogs, unless a 
p-chloro-benzyl group was used (VUF5205, pKi = 8.63). Remarkably, introduction of 
small alkyl groups resulted in reduced agonistic activity (di-methyl substitution, 
VUF5207, a  = 0.7) or neutral antagonism (isopropyl substitution, VUF4904). 
Substitution of the amine group with a cyclohexyl ring or a p-chlorobenzyl group 
resulted in (partial) inverse agonists. Our data show that only subtle changes at the 
amine function alter the pharmacological ctivity of the ligands. At present, we do not 
have an explanation for this phenomenon, but this series of ligands may be of great 
help to understand the mechanism of receptor (in)activation. Detailed studies with 
                          63
receptor mutants, the development of similar, rigid analogs and the generation of a 
three-dimensional computer model to rationalize receptor-ligand interaction may also 
be useful in this respect. 
 In conclusion, in this study we show that both the rat and human H3- receptors show 
a considerable level of constitutive activity when expressed at physiological 
expression levels in SK-N-MC cells. This observation has important consequences for 
the classification of H3- receptor ligands, which can now be classified as inverse 
agonists, neutral antagonists, and agonists. 
 Constitutive activity of the rat H3- receptor was also re-ported very recently by 
Morisset et al. (2000). Interestingly, the constitutive activity of the rat H3- receptor was 
suggested to regulate brain histamine release in both rat and mouse (Morisset et al., 
2000). The H3- receptor is, therefore, one of the few GPCRs for which it is known that 
they modulate important physiological processes by means of its constitutive activity. 
In light of the foreseen therapeutic application of H3- antagonists (Leurs et al., 1998), it 
remains to be established whether inverse agonists or neutral antagonists will be 
favored for clinical application.
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Fig. 5. Effect of impentamine and clobenpropit on the in vivo histamine release in the rat hypothalamus 
as measured by microdialysis. Drugs (10 pM) were infused in the hypothalamus via the microdialysis 
probe. Frac-tions were collected every 20  min and the amount of histamine was determined by HPLC, 
as described under Experimental  Procedures.*,a significant (P < 0.05) difference compared with basal 
levels of histamine release.
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